WO2001016295A1 - Nouveaux recepteurs peptidiques natriuretiques, composes d'interaction et procedes de regulation de la proliferation et/ou de la survie des neurones - Google Patents

Nouveaux recepteurs peptidiques natriuretiques, composes d'interaction et procedes de regulation de la proliferation et/ou de la survie des neurones Download PDF

Info

Publication number
WO2001016295A1
WO2001016295A1 PCT/US2000/024457 US0024457W WO0116295A1 WO 2001016295 A1 WO2001016295 A1 WO 2001016295A1 US 0024457 W US0024457 W US 0024457W WO 0116295 A1 WO0116295 A1 WO 0116295A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
cells
natriuretic
peptides
anp
Prior art date
Application number
PCT/US2000/024457
Other languages
English (en)
Other versions
WO2001016295A9 (fr
Inventor
James A. Waschek
Vincent Lelievre
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to AU73522/00A priority Critical patent/AU7352200A/en
Publication of WO2001016295A1 publication Critical patent/WO2001016295A1/fr
Publication of WO2001016295A9 publication Critical patent/WO2001016295A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin

Definitions

  • the present invention relates to compositions for and methods of regulating the proliferation and/or survival of neurons, using compounds, such as natriuretic peptides, that interact with natriuretic peptide receptors on neurons, and to methods of treating neuronal injury or degeneration.
  • the invention also relates to a novel receptor that responds to natriuretic peptides and neuropeptides and to the isolation and characterization of a novel natriuretic peptide type-C receptor.
  • Neuronal injury and neuronal degeneration occur as a result of stroke, brain, retina or spinal cord injuries, ischemia and reperfusion, as well as trauma from surgical procedures, and from other brain disorders and diseases.
  • Diseases such as Huntington's and Alzheimer's, as well as Parkinson's, and amyotrophic lateral sclerosis (ALS), which involve neuronal injury and death, present a serious, ongoing public health challenge to find adequate, cost-effective treatments.
  • ALS amyotrophic lateral sclerosis
  • enhanced proliferation and survival of neurons for transplants, such as brain transplants is an ongoing goal in medicine.
  • Neuronal tumors also present a significant, life threatening medical condition, particularly in children.
  • Malignant gliomas are highly aggressive brain tumors that are very resistant to current therapeutic approaches, including surgery, radiation, and chemotherapy. Uncontrolled glial proliferation and vascular invasion are two hallmark characteristics of malignant gliomas. These neoplasms affect approximately 17,000 Americans every year and are invariably fatal.
  • glioblastomas Invasive gliomas
  • the median survival time of affected patients is less than two years.
  • the extension of existing knowledge and the development of new, innovative approaches for the treatment of malignant brain tumors are essential.
  • peptide receptors have been studied as markers for various cancers (Reubi et al., Cancer Res. 57:1377-1386 (1997a)); Reubi et al., Gut 42:546-550 (1998); and Reubi et al., Gastroenterology 112:1197-1205 (1997b)). Procedures such as receptor scintigraphy may permit non-invasive localization of tumors, as has been shown for somatostatin and vasoactive intestinal peptide (VIP) (Krenning et al., Nucl. Med. Ann. 1-50 (1995)).
  • VIP vasoactive intestinal peptide
  • Therapeutic applications to inhibit tumor growth include use of peptidase-resistant analogs (Jensen, Digestion 58 (Supp. 1): 86-93 ( 1997)) or radiotherapy using radiolabeled peptides.
  • Natriuretic peptides include a family of the three structurally related peptide hormones: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and the type-C natriuretic peptide (CNP) (Needleman P. et al., Ann Rev Pharm Tox, 29:23-54 (1989); Espiner EA et al., Endocrinol Metab Clin North Am, 24(3):481-509 (1995)). Natriuretic peptides are primarily secreted from the myocardium and neurons.
  • ANP binds with high affinity to type A (“NPRA”) and C (“NPRC”) receptors (Nakao K, et al, J Hypertension, 10: 1 1 11-1 1 14 (1992); Anand-Srivastava MB et al., Pharmacol Rev, 45: 455-497 (1994)).
  • NPRA type A
  • NPRC type A receptor
  • CNP binds with highest affinity to type B ("NPRB") receptors
  • NPRB type B
  • Des-[Gln 18 , Ser 19 , Gly 20 , Leu 21 , Gly 22 ]-ANP 4-23 - NH 2 is a selective agonist for type C receptor (Maack T. et al., Science, 223:675-678 (1987)).
  • Natriuretic peptide receptors differ in their relative affinity for ANP analogues.
  • NPRA binds ANP and BNP with high affinity and CNP with very low affinity.
  • NPRB is relatively selective for CNP.
  • NPRC binds natriuretic peptides with the following affinity profile: ANP>CNP>BNP.
  • Receptor subtypes A and B contain a single transmembrane domain, and possess guanylate cyclase (GC) activity in their intracellular domain (Pandey KN et al., J Biol Chem, 265:12345-12348 (1990); Roller KJ, et al., Science, 252: 120-123 (1991)).
  • the type C receptor (NPRC) is similar to types A and B, but lacks the intracellular GC domain (Fuller F. et al, J Biol Chem, 263: 9395-9401 (1988)). Despite widespread expression of NPRC, initial studies were unable to identify its signaling pathways.
  • Natriuretic peptides were first revealed to be hormones produced by the heart that regulate vascular tone, sodium and water and other cardiovascular functions through action on the kidney and vascular smooth muscle. Natriuretic peptides regulate central and peripheral body fluid and blood pressure (Goetz K (1988) Am J Physiol. 254:E1-15; Brenner BM, et al. (1990). Physiol Rev, 70:665-699). All three natriuretic peptides are expressed in the adult brain, where one function appears to involve central control of the cardiovascular system.
  • the peptides have been shown to inhibit the proliferation of several cell types, including vascular smooth muscle cells (Cahill PA et al., Biochem Biophys Res Comm, 179: 1606-161313 (1991)) (type C receptors), kidney mesangial cells (Appel RG, Am J Physiol, 259: E312-E318 (1990); Haneda M. et al., Biochem Biophys Res Comm, 192: 642-648 (1993); Segawa K.
  • a report indicated that the type-C receptors mediate inhibition of astrocyte proliferation via inhibition of a MAP kinase pathway (Prins BA. et al, J Biol Chem, 271, 14156-14162 (1996)).
  • ANP stimulated the proliferation of embryonic cardiomyocytes (Koide M. et al., Differentiation, 61 : 1-1120 (1996)), and both CNP and BNP were found to stimulate longitudinal bone growth in vitro (Yasoda A. et al., J. Biol Chem, 273: 1 1695-1 170021 (1998)) (type B receptors).
  • transgenic mice over-expressing BNP and NPRC knockout mice exhibited pronounced skeletal overgrowth (Suda M. et al., Proc Natl Acad Sci U SA, 95:2337-42 (1998); Matsukawa N. et al., Proc. Natl Acad Sci USA, 96:7403-7408 (1999)) (type B receptors).
  • Neuroblastoma cells have been reported to express natriuretic peptides (Niimura S. et al., Res Comm Chem Pathol Pharmacol, 63: 189-200 26 (1989)) and their receptors (Delporte C. et al., Eur J Pharmacol, 207: 81-88 (1991)) (type A or B receptors). They have also been reported to secrete certain endopeptidases (Delporte C. et al., Eur J Pharmacol, 227:247-5628 (1992)) that are capable of cleaving natriuretic peptides.
  • Receptors for peptides in the atrial natriuretic peptide (ANP) family appear to be expressed in the proliferative zone of the embryonic brain, indicating a potential role of natriuretic peptides in neurogenesis.
  • Neuroblasts in the embryonic brain and peripheral nervous system, and neuroblastoma tumors also express VTP- and pituitary adenylate cyclase-activating peptide (PACAP)-related neuropeptides as well as natriuretic peptides, and receptors that respond to these peptides.
  • PACAP pituitary adenylate cyclase-activating peptide
  • VTP and PACAP have been shown to regulate the proliferation of both normal cultured embryonic neuroblasts (Waschek et al., PNAS (USA), supra; Pincus et al, Nature 343:564- 567 (1990); and DiCicco-Bloom and Deutsch, Reg. Pept. 37:319A (1992)) and neuroblastoma tumor cell lines (O'Dorisio et al., supra; Pence et al., supra; Wollman et al., Brain Res. 624:339-341 (1993); Muller et al, Mol.
  • PHI Peptide Histidine Isoleucine
  • Natriuretic peptides and analogs potently inhibit the proliferation of cultured astrocytes (Prins BA, et al. (1996) J Biol Chem 271 : 14156-62; Levin ER, and HJ Frank (1991) Am J Physiol 261 :R453-7; Hu RM, and ER Levin (1994) J Clin Invest 93: 1820-7). This action appears to be mediated by an NPRC-like receptor, and is associated with an inhibition of MAP kinase activity and decreased fibroblast growth factor-2 production. Other groups have shown that astrocytes also express GC-coupled natriuretic receptors (Sumners C, et al. (1994) Glia 11: 110-6).
  • CNP gene transcripts were produced in astrocytes, indicating the potential for an autocrine/paracrine growth loop for the natriuretic peptide/receptor system in glial cells and associated blood vessels (Yeung VT, et al. (1996) Neuroreport, 7:1709-12).
  • the present invention provides methods and compositions for regulating the proliferation and/or prolonging the survival of neuronal cells.
  • the compositions consist of compounds that act on natriuretic peptide receptors, such as Type A, B and C receptors, directly on neurons or indirectly on neurons via Schwann cells, astrocyte, or other glial cell types.
  • atrial natriuretic peptides are used to inhibit the proliferation of neurons, for example to treat neuronal tumors.
  • ANPs are used to increase the proliferation and or prolong the survival of neurons, for example to repair injury to nerves or to treat neurodegenerative diseases, to enhance survival of transplanted neurons or to propagate neurons in vitro.
  • the invention further includes methods for treating neuronal injury or degeneration in a subject using the compositions of the invention in an effective dose to increase the proliferation and/or prolong the survival of neurons subject to injury or degeneration.
  • the methods of the invention include methods of diagnosing neuronal tumors by detecting receptors of natriuretic peptides and/or neuropeptides expressed on neuronal tumors and/or as prognostic or therapeutic indicator in tumor biopsies.
  • the invention also includes a new receptor, natriuretic peptide neuropeptide receptor or "NNPR", that is expressed on neuronal tumor cells and in the developing brain, and reacts with natriuretic peptides and neuropeptides, and methods of using this receptor.
  • NPR natriuretic peptide neuropeptide receptor
  • the invention provides a novel natriuretic peptide type-C receptor that is expressed in Xenopus oocytes and can alter the signaling activity of unrelated receptors.
  • Figure 1A-E are bar graphs depicting the results of thymidine inco ⁇ oration assays in Neuro2a cells stimulated for 5 hr with increasing concentrations of ANP peptides in the absence (A) and presence (D-E) of signal pathway inhibitors as described in Example I, infra.
  • A Control (no inhibitor);
  • B Protein kinase A inhibitor H89 (20 ⁇ M);
  • C Protein kinase C inhibitor GF109203X (10 ⁇ M);
  • D MEK1/2 inhibitor PD98059 (30 ⁇ M);
  • E Protein kinase G inhibitor Rp-8-pCTP-cGMPS (15 ⁇ M).
  • the panel in lower right gives peptide representations. Data were the mean ⁇ SEM of four independent experiments each performed in triplicate. Statistical analysis of the data (ANOVA) were performed (* p ⁇ 0.05, ** p ⁇ 0.01, ***p ⁇ 0.005)).
  • Figure 2 is a bar graph depicting the results of thymidine inco ⁇ oration assays in Neuro2a cells stimulated for 5 hr with increasing concentrations of ANP peptides in the absence or presence of 20 ⁇ g/ml HS 142.1 antagonist as described in Example I, infra.
  • A ANP
  • B CNP
  • C DesANP 4-23 .
  • Data were the mean ⁇ SEM of 2 independent experiments each performed in triplicate.
  • Statistical analysis of the data was performed (* p ⁇ 0.05, ** p ⁇ 0.01, ***p ⁇ 0.005).
  • Figure 3 A-C are graphs depicting displacement of different radiotracers ( 125 I: A; 125 I- PACAP:B and I-PHLC) by increasing concentrations of native peptides and analogues, as described in Example I, infra. (Binding was performed at 4EC on intact cells. Incubation times were 150, 150 and 180 minutes for the respective radioligands ANP, PACAP and PHI. Symbols for displacing peptides are the same for the three sets of experiments in Figure 3 A. Data were the mean ⁇ SEM of three independent experiments, each performed in triplicates. Graphs and curve fittings were computerized using Graphprism software (1ST). Parameters extracted from curves are shown in Table I.)
  • FIGS. 1 and 1 Figure 4 A-B are graphs depicting displacement of the I- ANP radiotracers by increasing concentrations of native peptides and analogues and sensitivity to HS- 142-1, as described in Example I, infra. (Binding was performed at 4°C for 150 min on intact cells. A: total 5 I- ANP bound in the presence of increasing concentrations of HS- 142-1. B: displacement of remaining (HS- 142-1 insensitive) 125 I- ANP by increasing concentrations of desANP 4-23 . Data were the mean ⁇ SEM of 3 independent experiments each performed in triplicates. Graphs and curve fittings were computerized using Graphprism software (ISI). Parameters extracted from curves are shown in Table I, infra).
  • Figure 5 A-B is a graph showing the dose-dependent effect of natriuretic peptides on intracellular cGMP levels in Neuro-2a cells, as described in Example I, infra. Peptide- induction of the cGMP production in Neuro-2a in the presence of IBMX (10 ⁇ M).
  • Figure 6 A-C are graphs showing the modulation of intracellular calcium concentration in response to neuropeptides and natriuretic peptides in Neuro2a cells as described in Example I, infra. (Cells were growing on glass coverslips; Calcium movements induced by the indicated peptides were recorded for 250 sec, before addition of the calibration reagents.
  • B Effects of CNP or PACAP-38 in the same conditions.
  • C Effects of desANP 4-23 , followed by VTP.
  • Figure 7 is copies of photographs of Northern blot analysis of the expression of natriuretic peptide receptors A-ANPR, B-ANPR and C-ANPR in Neuro2a cells, as described in Example I, infra.
  • Northern blots were prepared as described in Example I. Lanes contained 15 ⁇ g of polyA-selected RNA, extracted from Neuro2a, kidney, spleen and 15 ⁇ g of total RNA from brain, respectively. Hybridizations were performed overnight at 45°C with the corresponding probes as described in Example I. Ribosomal sub units 28 and 18S were used as size markers.
  • Figure 8 A and B is an illustration (8A) depicting polymerase chain reaction (PCR) amplification of NPRC receptor in mouse neuroblastoma cells and in isolated neural tube from E10 embryos, and the resulting autoradiographs (8B), as described in Example I, infra.
  • PCR polymerase chain reaction
  • Figure 8A various sets of primers were designed to cover the entire sequence encoding the clearance receptor. Amplified products were run on 2% agarose gel and photographed under UV transillumination after 90 minutes migration at 80V. After Southern transfer, membranes were hybridized with 32P-endlabelled internal oligonucleotides as described in Example I.
  • Figure 8B is autoradiographs of the corresponding PCR reactions, showing specific hybridizations with PCR reaction products from neural tube samples, but none from Neuro2a RNA).
  • Figure 9 is an illustration summarizing types of receptors for neuropeptides and natriuretic peptides observed in Neuro2a cells as described in Example I, infra, and the putative pathways involved in modulation of neuronal proliferation.
  • AD adenylate cyclase
  • DAG diacylglycerol
  • G G proteins
  • GC guanylate cyclase
  • RTK tyrosine kinase/receptor
  • Figure 10 are bar graphs depicting the thymidine inco ⁇ oration assays in 4 different neuroblastoma cell lines, as described in Example ⁇ , infra. Cells were incubated for 5 hr with increasing concentrations of natriuretic peptide analogs. Peptide bar codes are given in the first graph. Data were the mean ⁇ SEM of four independent experiments each performed in triplicate. Statistical analysis of the data (ANOVA) was performed (* p ⁇ 0.05, ** p ⁇ 0.01, ***p ⁇ 0.005)
  • Figure 11 depicts the effects of protein kinase G (PKG) inhibitor on natriuretic peptide- induced modulation of thymidine inco ⁇ oration in Neuro2a cells, as described in Example TJ, infra.
  • Data are the mean ⁇ SEM of two independent experiments each performed in triplicate.
  • Statistical analysis of the data has been performed (* p ⁇ 0.05, ** p ⁇ 0.01, ***p ⁇ 0.005).
  • Figure 12 illustrates the effects of MAP kinase inhibitor on natriuretic peptide-induced modulation of thymidine inco ⁇ oration in Neuro2a cells, as described in Example II, infra. Insert gives peptide representations. Data were the mean ⁇ SEM of two independent experiments each performed in triplicate. Statistical analysis of the data (ANOVA) was performed (* p ⁇ 0.05, ** p ⁇ 0.01, ***p ⁇ 0.005).
  • Figure 13 shows the thymidine inco ⁇ oration assays in Neuro2a cells stimulated for 5 hr with increasing concentrations of natriuretic peptides in the absence or presence of 20 ⁇ g/ml HS 142.1 antagonist, as described in Example II, infra. Data were the mean ⁇ SEM of 2 independent experiments each performed in triplicate. Statistical analysis of the data (ANOVA) was performed (* p ⁇ 0.05, ** pO.Ol, ***p ⁇ 0.005).
  • Figure 14 illustrates the dose-dependent effect of natriuretic peptides on intracellular cGMP levels in Neuro-2a cells, as described in Example ⁇ , infra.
  • Figure 15 shows the modulation of intracellular calcium concentration in response to neuropeptides and natriuretic peptides in Neuro2a cells, as described in Example II, infra.
  • Figure 16 illustrates the comparison of displacement of the I- ANP binding by increasing concentrations of native peptides in NG108 and Neuro2a cells, as described in Example ⁇ , infra. Parameters extracted from curves are shown in Table II.
  • Figure 17 shows the displacement of the I- ANP radiotracer by increasing concentrations of native peptides and analogues and sensitivity to HS- 142-1 as described
  • Example TJ infra
  • A two site-binding displacements of I-ANP by various peptides in the absence of HS- 142-1 ;
  • B 3 I-ANP specifically displaced by increasing concentrations of HS- 142-1;
  • C displacement 125 I-ANP by increasing concentrations of desANP 4-23 in Neuro2a cells treated with 25 ⁇ g/ml HS-142-1).
  • Data were the mean ⁇ SEM of 2 independent experiments each performed in triplicates.
  • Graphs and curve fittings were computerized using Graphprism software (ISI).
  • Figure 18 depicts Northern blot analysis of natriuretic peptide receptors NPR-A, NPR-B and NPR-C gene expression in Neuro2a cells, as described in Example U, infra.
  • Figure 19 depicts NPRC gene expression in El 0.5 mouse embryos detected by in situ hybridization, as described in Example in, infra. All are coronal sections. Dorsal/ventral and anterior/posterior orientations are indicated. Panel D is a dark field view of C (to better visualize the silver grains); all others are bright field photos at different levels of the embryo.
  • Figure 20 illustrates the NPRC gene expression in El 2.5 mouse embryos, as described in
  • Example III infra. Panels A, B, I and J are coronal sections; C and D are in a plane parallel to the spinal cord, G and H are sagittal sections. B. D, F, and J, are dark field views of A, C, E, and I, respectively. H is a magnification of the area within the rectangle in G. Dorsal/ventral and anterior/posterior orientations are indicated.
  • PNVP perineural vascular plexus
  • DRG dorsal root ganglia
  • 5n trigeminal nerve
  • 5g trigeminal ganglia
  • 5max maxillary nerve
  • 5 man mandibular nerve
  • RP roof plate
  • FP floor plate
  • LV lateral ventricle.
  • I and J point to one of several capillaries (Ca) shown in this section of the telencephalon.
  • Figure 21 shows the NPRB gene expression in El 0.5 mouse embryos, as described in
  • Example HI infra.
  • a and B are bright and dark field views, respectively, of a coronal section of the hindbrain (dorsal/ventral orientation is indicated). The arrows point to the layer of postmitotic neurons.
  • C is a dark field view in the frontal plane of the spinal cord
  • Figure 22 illustrates the CNP gene expression in El 2.5 (A-D) and El 4.5 (E-F) mouse embryos.
  • B, D, and E are bright field views of A, C, and E, respectively, as described in
  • Example UI infra.
  • a and B are sagittal sections.
  • C-F are coronal sections.
  • M medulla
  • SC spinal cord
  • VC primordial vertebrate
  • CC central canal of spinal cord
  • 4V fourth ventricle
  • 3V third ventricle
  • Du cells associated with the dura. Arrows in C and D point to hybridizing transcripts in the VZ of the dorsal part of the spinal cord.
  • Figure 23 shows the inhibition of neuroblast proliferation by natriuretic peptides, as described in Example HI, infra.
  • Figure 24 depicts the nucleotide and deduced amino acid sequences of a full-length cDNA encoding a Xenopus type-C natriuretic peptide receptor (NPR-C), as described in Example VI, infra.
  • the black box indicated the location of the putative transmembrane spanning domain. Codons and Cys residues (in Bold) locate the putative inter and intrachains disulfide bounds, whereas grey boxes point out NXT/S sequences implicated in potential N- glycosylation.
  • Figure 25 illustrates the alignment of the deduced amino acid sequence of XNPR-C with mammalian and eel sequences of type-C natriuretic peptide receptors, as described in Example VI, infra. Dark gray boxes delineate identities between all the four sequences presented, whereas light gray boxes point out the amino acids specifically conserved between Xenopus and Eel.
  • Figure 26 shows the alignment of the deduced amino acid sequence of XNPR-C receptor with the Xenopus guanylate cyclases XGC-1 and XGC-2 (Genbank Accession number AB 025111.1 and 025111.2), as described in Example VI, infra. Dark gray boxes delineate the putative transmembrane spanning domain presented, whereas light gray boxes point out the amino acids specifically conserved between XNPR-C and XGC-1 or XGC-2. Black boxes locate cystein residues potentially implicated within disulfide bounds. Amino acids that belong to the natriuretic peptide receptor motif and that are conserved between NPR-C and GC are indicated in bold characters.
  • Figure 27 shows the structural features of the Xenopus NPR-C.
  • XNPR-C presented a short intracellular tail, an unique transmembrane domain, and a extracellular portion characterized by the presence of 6 cystein residues identified in 2 intramolecular loops, and 2 intermolecular bounds, as described in Example VI, infra.
  • the 3 potential sites for N-glycosylation are indicated by gray squares.
  • Figure 28 depicts the receptor binding studies on Xenopus oocytes injected with capped mRNA encoding XNPR-C receptor, as described in Example VI, infra.
  • Figure 29 illustrates the receptor binding studies on Xenopus oocytes injected with capped mRNA encoding XNPR-C receptor, as described in Example VI, infra.
  • Figure 30 depicts the modulation of cAMP contents by natriuretic peptides (A) or neuropeptides (B) in oocytes overexpressing XNPR-C, as described in Example VI, infra.
  • Figure 31 illustrates the modulation of cAMP contents by neuropeptides (A) or natriuretic peptides (B) in oocytes overexpressing PAC-1, as described in Example VI, infra.
  • Figure 32 shows the modulation of cAMP contents by neuropeptides or natriuretic peptides in oocytes overexpressing XNPR-C and PAC-1, as described in Example VI, infra.
  • the methods of the invention are based on the discovery that peptide receptor subtypes on neurons and related cells, including a new receptor, natriuretic peptide neuropeptide receptor or "NNPR,” respond to compounds such as natriuretic peptides, for example atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), or type-C natriuretic peptide (CNP), as well as PHI-related neuropeptides, causing effects on the proliferation and/or survival of neurons.
  • Proliferation as used herein, means an effective increase in the number of cells treated with the compound of the invention e.g. natriuretic peptide as compared to non-treated cells.
  • An effective increase in the number of cells so treated can occur as a result of an increase in survival, by an increase in mitotic rate, or a combination of both an increase in survival and an increase in mitotic rate.
  • Prolonged or enhanced survival means that the cells exhibit longer individual survival rates and healthy function.
  • the invention is also based on the discovery of a novel receptor, NNPR, expressed on neuronal tumor cells, that interacts with natriuretic peptides, such as ANPs, as well as PM- related neuropeptides such as PHI, VTP and PACAP.
  • the methods of the invention are also based on the finding that natriuretic receptor subtypes are expressed on developing Schwann cells and newly formed blood vessels in the developing brain, indicating that natriuretic peptides may also act indirectly on glial cells to regulate the proliferation and survival of neurons, or on blood vessel cells as they invade new brain tissue or brain tumors.
  • the invention further provides a novel natriuretic peptide type-C receptor that is expressed in Xenopus oocytes and have shown ability to alter the signaling activity of unrelated receptors.
  • Cell types that may be regulated by the methods of the invention include but are not limited to normal and injured cells of the nervous system, such as neurons, Schwann cells, glial cells, oligodendrocytes, microglia, astrocytes, developing blood vessel cells, ganglion satellite cells, and immune cells involved in nerve injury or degeneration.
  • normal and injured cells of the nervous system such as neurons, Schwann cells, glial cells, oligodendrocytes, microglia, astrocytes, developing blood vessel cells, ganglion satellite cells, and immune cells involved in nerve injury or degeneration.
  • the invention provides methods and compositions for regulating the proliferation and/or prolonging the survival of neurons using compounds, such as natriuretic peptides, including ANPs, BNPs or CNPs, and/or PHI-related neuropeptides, such as PHI, VTP and PACAP, their analogues, derivatives or equivalents of these compounds, having the ability to stimulate or inhibit proliferation of neurons, and/or to prolong the survival of neurons, via interaction with their corresponding peptide receptors.
  • the NNPR receptor may be used for a number of purposes, including, but not limited to use as a diagnostic and or prognostic marker of neuronal cancers, generation of antibodies, and as targets for various therapeutic modalities, by directing agents to cancer cells via the NNPR.
  • the invention further provides methods and compositions for diagnosing the presence of neuronal tumors by detecting peptide receptors, such as type C receptors and the NNPR receptor of the invention, using labeled natriuretic peptides, PHI-related neuropeptides, or analogues, derivatives or fragments of these compounds.
  • the invention also provides methods for treating diseases or dysfunctions caused by injured or dying or dead neurons by increasing the proliferation and/or survival of the neurons, and for treating neuronal tumors by interfering with the proliferation and or survival of neuronal tumor cells using the compositions of the invention that stimulate peptide receptors such as NNPR on the cells, or inhibit type A or B receptors.
  • Still other methods of the invention are for prolonging survival of neurons used for transplants or for propagation of neurons in vitro.
  • the compounds of the invention also include agonists or antagonists of the natriuretic peptides and/or PHI-related neuropeptides, for example to interfere with the binding of endogenous natriuretic peptides and/or PHI-related neuropeptides, to their respective receptors on neurons.
  • agonists of the peptides can be used to stimulate the NNPR receptor on the tumor cells.
  • antagonists of the peptides such as antibodies against natriuretic peptides or neuropeptides, or endopeptidases that digest such peptides, and including anti-sense oligonucleotides directed against the peptides or their receptors, can be used to reduce the availability of endogenous natriuretic peptides or interfere with the interaction of the peptides with type A or B receptors, which may be stimulating neuronal tumor growth.
  • the compounds further include antagonists of the type A, B, C or C-like (e.g. NNPR) receptors, such as antibodies, that are administered to prevent the stimulatory or inhibitory responses of these receptors.
  • the guiding principle for carrying out the methods of the invention is to select agonists or antagonists of the natriuretic peptides and/or neuropeptides, and agonists or antagonists of their respective peptide receptor subtypes, to decrease proliferation of tumor cells, or to enhance proliferation and/or promote survival of healthy, damaged or dying neurons in vitro or in vivo, using the compositions of the present invention.
  • proliferation and enhanced survival of neurons is desired, for example, to ameliorate neurodegenerative disease
  • agonists of the natriuretic peptides such as ANPs, or of PHI-related neuropeptides (e.g. PHI, VIP or PACAP), or the peptides themselves, are administered to stimulate proliferation via type A or type B receptors expressed on neurons.
  • Production of endogenous peptides in vivo can also be addressed, using for example, agents that stimulate or inhibit expression of the peptides, such as anti-sense oligonucleotides directed against the peptides.
  • the response of peptide receptors such as subtype C or the NNPR receptor of the present invention, expressed on neuronal tumor cells is stimulated using ligands for the receptors, such as natriuretic peptides and/or PHI-related neuropeptides, or their agonists.
  • Antibodies against natriuretic peptides are known (Clerico et al., J. Endocrinol. Investl, 21:3 170-9 (1998)), Numata et al., Clin. Chem. 44:5, 1008-13 (1998)), as are antibodies against VIP related neuropeptides (Lundeberg and Nordlind, Arch Dermatol Res. 291(4):201-206 (1999)).
  • antibodies such as monoclonal antibodies
  • hybridoma fusion techniques or by techniques that use EBV- immortalization methods.
  • EBV- immortalization methods See, e.g. Kohler and Milstein, Nature, 256:495-97 (1975); Brown et al., J. Immunol, 127 (2):539-46 (1981); Brown et al., J. Biol. Chem., 255:4980- 83 (1980); Yeh et al., Proc. Nat'l Acad. Sci. (USA), 76 (6):2927-31 (1976); and Yeh et al., Int. J. Cancer, 29:269-75 (1982)).
  • Chimeric (mouse-human e.g., humanized antibodies) or human monoclonal antibodies may be preferable to murine antibodies for some therapeutic uses, because patients treated with mouse antibodies generate human anti-mouse antibodies.
  • Chimeric mouse-human monoclonal antibodies reactive with the antigen can be produced, for example, by techniques recently developed for the production of chimeric antibodies (Oi et al., Biotechnologies 4(3):214-221 (1986); Liu et al., Proc. Nat'l. Acad. Sci. (USA) 84:3439-43 (1987)).
  • Novel antibodies of mouse or human origin can be also made to the antigen having the appropriate biological functions.
  • human monoclonal antibodies may be made by using the antigen, e.g. a natriuretic peptide, to sensitize human lymphocytes to the antigen in vitro followed by EBV-transformation or hybridization of the antigen-sensitized lymphocytes with mouse or human lymphocytes, as described by Borrebaeck et al. (Proc. Nat'l. Acad. Sci. (USA) 85:3995-99 (1988)).
  • the antigen e.g. a natriuretic peptide
  • Endopeptidases that digest natriuretic peptides are known (Delporte et al., Eur. J. Pharmacol. 207:81-88 (1991)).
  • Antagonists of the natriuretic peptides and PHI-related neuropeptides for use in the present invention include antisense oligonucleotides that block the expression of the genes encoding the peptides within cells by binding a complementary messenger RNA (mRNA) and preventing its translation (Wagner, Nature 372:332-335 (1994); and Crooke and Lebleu, Antisense Research and Applications, CRC Press, Boca Raton (1993)). Gene inhibition may be measured by determining the degradation of the target RNA.
  • mRNA complementary messenger RNA
  • Antisense DNA and RNA can be prepared by methods known in the art for synthesis of RNA including chemical synthesis such as solid phase phosphoramidite chemical synthesis or in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule.
  • the DNA sequences may be inco ⁇ orated into vectors with RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines.
  • the potency of antisense oligonucleotides for inhibiting the target peptides may be enhanced using various methods including 1) addition of polylysine (Leonetti et al.,
  • Recent techniques for enhancing delivery include the conjugation of the antisense oligonucleotides to a fusogenic peptide, e.g. derived from an influenza hemagglutinin envelope protein (Bongartz et al., Nucleic Acids Res. 22(22):4681-4688 (1994)).
  • a fusogenic peptide e.g. derived from an influenza hemagglutinin envelope protein
  • Additional suitable antagonists of the peptides can be readily determined using methods known to the art to screen candidate agent molecules for binding to the peptides, such as assays for detecting the ability of a candidate agent to block binding of radiolabeled peptide to natriuretic receptors expressed on cells.
  • Additional embodiments of the invention include compounds that promote or interfere with the specific signaling pathways involved in the response of peptide receptors to the binding of natriuretic peptides, resulting in enhanced or decreased neuron proliferation and or survival.
  • Such compounds include those, which inhibit or promote the signaling pathway, for example by inhibiting a key compound in the pathway.
  • MAP kinase inhibitors may be used to inhibit proliferation of neuronal tumors expressing these receptors.
  • compounds such as cyclic GMP analogues can be used to increase proliferation and/or survival of neurons expressing type A or B (GC) peptide receptors.
  • Yet another embodiment of the invention includes a novel receptor, NNPR, that responds to natriuretic peptides (e.g., ANP) and neuropeptides (e.g., PHI) that is expressed on neuronal tumor cells.
  • NNPR a novel receptor that responds to natriuretic peptides
  • neuropeptides e.g., PHI
  • the same, or another novel receptor is proposed based on the in situ hybridization results, infra, showing that gene expression for none of the three known receptors is detectable in a part of the develping brain that avidly binds radiolabeled natriuretic peptides.
  • This receptor is isolated and cloned using methods known in the art.
  • the NNPR is cloned using either injection of in vitro transcribed mRNA into Xenopus oocytes, or by transfection of an eukaryotic expression library into mammalian cells.
  • the Xenopus system is first evaluated for a response to PHJ or desANP 4-23 after injection of polyA-selected RNA from Neuro 2a cells. The nature of specific current (calcium, chloride or potassium) is then determined to optimize the signal.
  • RNA may be used from another source, such as another neuroblastoma cell line or retinoic acid- or phorbol ester-differentiated Neuro 2a cells.
  • the NNPR receptor can be also cloned using expression cloning in mammalian cells such as COS cells using radioligand binding which depends only on high affinity binding of the radiolabeled ligand. Because the NNPR binds both PHI and desANP - 23 with high affinity, either ligand or both can be used to detect expression. For example, the NNPR binds 125 I- PHI and 125 I-ANP, but is selectively displaced by either PH or desANP 4- 3 .
  • the method for cloning the NNPR uses methodology known in the art, such as that described by Ishihara et al., EMBOJ. 10:1635-1641 (1991), used to isolate the secretin receptor cDNA.
  • An existing neuroblastoma eukaryotic expression library can use cells, such as NG108 cells to clone the gamma opiate receptor (Evans et al., Science 258:1952-1955 (1992)), or SK-N-SH to clone the plasma membrane noradrenaline transporter (Pachoiczyk et al., Nature 350:350-354 (1991)), or a library can be constructed from Neuro2a cells using an eukaryotic expression vector such as pcDNA (InVitrogen).
  • the library is screened using standard methods (Evans et al., supra). Briefly, 10 to 12 subdivisions are electroporated into COS cells. After transfection, cells are then transferred to tissue culture plates, and after three days, screened for PHI binding with I-PHJ. Plates are then washed and exposed to Cronex film (DuPont). After alignment of developed film with the plates, DNA from positive cells is extracted by the method of Hirt (J. Mol. Biol. 26:365-369 (1967)), transfected into competent bacteria, then retransfected into COS cells (Farnsworth et al., Nature 376:524-527 (1995)). This procedure can be repeated until a single clone is obtained.
  • secondary and subsequent purification can be carried out using sib selection.
  • the clone can be verified as encoding NNPR, if it recapitulates the correct radioligand binding/displacement profiles: e.g. it should bind 125 1- PHI, and be selective displaced by either PHI or desANP 4- 3 , and should also bind I-ANP and be efficiently displaced by either PHI or desANP 4 . 2 .
  • Cells other than COS cells can be tested for expression of NNPR and used for cloning (Simonsen and Lodish, supra)
  • the compounds of the invention may be used in pharmaceutical compositions for treating neuronal injury or diseases which result in neuronal degeneration, for example from stroke, brain, retina or spinal cord injuries, ischemia and reperfiision or other brain disorders and diseases as well as trauma associated with neurosurgical procedures or accidents.
  • Brain disorders and diseases to be treated using the methods of the invention include, but are not limited to Huntingdon's disease, Alzheimer's disease, epilepsy, lathyrism, amyotrophic laterial sclerosis, and Parkinsonian dementia.
  • the compounds of the invention may also be used to promote survival and function of transplanted neurons.
  • compositions of the inventions can be administered as a homogenous solution, i.e. containing only one kind of peptide which recognize a receptor.
  • the pharmaceutical composition can contain a heterogeneous solution, i.e. containing a combination of different natriuretic peptides or multiple natriuretic peptides and/or PHI related peptides, that recognize multiple different receptors.
  • the compounds of the invention may also be used to treat neuronal tumors and other forms of excessive neuronal cell proliferation, by decreasing proliferation and/or survival of the neurons.
  • the novel NNPR receptor of the invention can also be used in methods of the invention.
  • this receptor can be used as a target for natriuretic peptides or neuropeptides, or mimics of these compounds, to inhibit proliferation of tumor cells expressing this novel receptor, and/or for ligands directed to the receptor for tumor cell killing, such as antibodies against the receptor, or radiotherapy using radiolabeled peptides.
  • compositions of the invention to treat neuronal tumors can be achieved using animal tumor models, such as those known in the art (e.g. Cortes et al., Gene Therapy 5(11):1499-1507 (1998)).
  • animal tumor models such as those known in the art (e.g. Cortes et al., Gene Therapy 5(11):1499-1507 (1998)).
  • neuroblastomas can be inoculated into an animal such as a rat.
  • an anti-tumor composition of the invention such as a natriuretic peptide, for example ANP, can be administered into the animal subject to stimulate type C receptors, and/or to stimulate the novel NNPR receptor of the invention to inhibit tumor cell proliferation.
  • Adminstration can be through any art recognized means.
  • administration is by infusion, e.g., using a cannula connected by catheter tube to a mini-osmotic pump.
  • the effects of the composition on tumor volume can be monitored, for example using magnetic resonance imaging (MRI) over periods of time to detect the size of the neuronal tumor in the animal.
  • Control animals can be used which also have neuronal tumors, but do not have the compositions of the invention administered.
  • a decrease in the tumor volume over time relative to the tumor volume in untreated animals can indicate tumor regression as a result of administration of the compositions of the invention.
  • the methods of treating injured neurons or neuronal degeneration from diseases or injury, of enhancing neuron survival for transplants, or for treating neuronal tumors include administering to a subject an effective dose of the compounds of the invention for interacting with peptide receptors, such as NNPR, on a cell.
  • peptide receptors such as NNPR
  • neuronal tumors expressing the NNPR receptor of the invention and/or C-type receptors can be treated using radiolabeled peptides for radiotherapy, for example, or peptidase-resistant analogues of ANP and/or PHI-related neuropeptides.
  • the effective dose will enhance the proliferation of neurons and/or prolong the survival of neurons, slowing neuronal degeneration or death, as compared to the proliferation and/or survival of neurons in an untreated subject.
  • the effective dose can result in a decrease in proliferation and/or survival of the neurons afflicted by the tumor, as compared to proliferation and/or survival of untreated neuronal tumor cells.
  • compositions can be used in both the peripheral nervous system and the central nervous system.
  • the compositions of the present invention can also be administered in combination with other compounds and agents for treating neuronal injury or disease, such as glutamate receptor antagonists or glucocorticoids.
  • the compounds can be administered in a suitable pharmaceutical carrier in an effective dose so as to result in enhanced neuronal proliferation and/or survival.
  • the compositions of the present invention can be administered in an amount effective to inhibit proliferation of neuronal tumors.
  • the peptides may also be introduced as nucleic acid encoding the gene for the compounds for expression in vivo.
  • the nucleic acid can be directly introduced into a subject as "naked DNA", or is introduced in a retroviral vector, or cells containing recombinant vectors that include the nucleic acid, for use in gene therapy methods in vivo to increase proliferation and/or survival of neurons, for example to treat neurodegenerative diseases, or to prolong the survival of transplanted neurons.
  • the effective dosages and modes of administration are made in accordance with accepted medical practices taking into account the clinical condition of the individual subject (e.g. severity and course of the disease), the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. Accordingly, the dosages of the compositions of the invention for treatment of a subject are to be titrated to the individual subject. For example, the interrelationship of dosages for animals of various sizes and species and humans based on mg/m of surface area is described by Freireich et al., Cancer Chemother. Rep. 50(4):219-244 (1966).
  • the "effective dose” can be determined by procedures known in the art, and must be such as to achieve a discernible change in the proliferation and/or survival of neurons, including but not limited to increased neuronal proliferation over that observed in untreated neurons for enhancing survival of the neurons, or decreased proliferation over that observed for untreated neurons for treating neuronal tumors.
  • Adjustments in the dosage regimen for treatment may be made to optimize the proliferation or inhibition, e.g. doses may be divided and administered on a daily basis, or the dose reduced proportionally depending on the situation, e.g. several divided doses may be administered daily or proportionally reduced.
  • the doses of the compositions of the invention required for treatments may be further refined with schedule optimization.
  • compositions of the invention are administered initially by intravenous injection to bring blood levels to a suitable level.
  • the patient's levels of the compounds that interact with the natriuretic peptide receptor subtypes are then maintained by an oral dosage form, although other forms of administration, dependent upon the patient's condition and as indicated above, can be used.
  • the quantity of compounds to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 mg/kg to 10 mg/kg per day.
  • compositions can be administered in a variety of manners, in pharmaceutically acceptable forms, alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles.
  • the compositions can be administered orally, subcutaneously or parenterally, including intravenous, intraarterial, intramuscular, intraperitoneally and intranasally, as well as using intrathecal and infusion techniques depending on dosing requirements and other factors known to those skilled in the art. Implants of the compounds may also be useful.
  • compositions of the invention When administering parenterally, the compositions of the invention will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).
  • the pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • the carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Nonaqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, may also be used as solvent systems for compound compositions.
  • various additives which enhance the stability, sterility, and isotonicity of the compositions including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added.
  • antimicrobial preservatives including antimicrobial preservatives, antioxidants, chelating agents, and buffers
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Prolonged abso ⁇ tion of the injectable pharmaceutical form can be brought about by the use of agents delaying abso ⁇ tion, for example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds.
  • Sterile injectable solutions can be prepared by inco ⁇ orating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with several of the other ingredients, as desired.
  • a pharmacological formulation can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres.
  • delivery systems useful in the present invention include: U.S. Pat. No. 5,225,182; U.S. Pat. No. 5,169,383; U.S. Pat. No. 5,167,616; U.S. Pat. No. 4,959,217; U.S. Pat. No.
  • a pharmacological formulation of the compounds utilized in the present invention can be administered orally to the patient. Conventional methods such as administering the compounds in tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the like are usable.
  • compositions of the invention orally, subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally, and intranasal administration as well as intrathecal and infusion techniques and retain the biological activity are preferred.
  • intrathecal delivery can be used with, for example, an Ommaya reservoir.
  • U.S. Pat. No. 5,455,044 provides for use of a dispersion system for CNS delivery or see U.S. Pat. No. 5,558,852 for a discussion of CNS delivery.
  • Pharmacological formulations that cross the blood-brain barrier can be prepared using known methods. Such formulations can take advantage of methods now available to produce chimeric peptides in which the compounds of the present invention are coupled to a brain transport vector allowing transportation across the barrier. (Pardridge, et al., West J. Med., 156(3):281-286 (1992); Pardridge, Pharm.
  • direct infusion into the cerebral spinal fluid can also be undertaken (Wilkins and Rengachary, Neurosurgery, Vol. IT, Ch. 190 (McGraw Hill), pp 1544-1570 (1982).
  • blood-brain-barrier disruption may be used in appropriate cases (Neuwelt et al., Ann. Int. Med. 93:137-139 (1980).
  • the blood brain barrier is generally "breached" in the area of the trauma and the compositions of the present invention can also be administered at the site of injury thereby delivering them directly to the site.
  • gene therapy utilizing the gene for compounds that interact with natriuretic peptide receptor subtypes can be employed using known gene therapy protocols.
  • the present invention provides a method of gene therapy for treating diseases which result in neuronal degeneration resulting from damage and death by administering the gene for the compounds so that the compounds are produced in situ where needed to counteract the damage or disease process.
  • pre-engineered T lymphocytes that contain the cloned gene under a strong promoter and that overexpress therefore, the gene product, can be used to deliver the compounds that interact with the natriuretic receptor subtypes on neurons to neural tissue (Kramer et al., supra, 1995).
  • the present invention provides for gene therapy utilizing vectors comprising an expression control sequence operatively linked to the nucleic acid sequence of genes for the compounds of the invention that interact with natriuretic peptide receptor subtypes on neurons for therapeutic uses.
  • Vectors are known or can be constructed by those skilled in the art and should contain all expression elements necessary to achieve the desired transcription of the sequences.
  • the vectors can be introduced into cells or tissues by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor, Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston, Mass.
  • Recombinant viral vectors are an example of vectors useful for in vivo expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity.
  • the vector to be used in the methods of the invention will depend on desired cell type to be targeted. For example, if neural cells are to be treated, then a vector specific for such neural cells will be used. Alternatively, cells can be transformed that target to the central nervous system.
  • Retroviral vectors can be used.
  • the vector's genome can be also engineered to encode and express the desired recombinant gene.
  • the specific type of vector will depend upon the intended application.
  • Retroviral vectors are also known and readily available within the art or can be constructed by one skilled in the art using well-known methodology.
  • the procedure can take advantage of their target specificity and consequently, do not have to be administered locally at the diseased site.
  • local administration may provide a quicker and more effective treatment
  • administration can also be performed by, for example, intravenous or subcutaneous injection into the subject.
  • Injection of the viral vectors into a spinal fluid can also be used as a mode of administration, especially in the case of neurodegenerative diseases.
  • the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection.
  • Transfection vehicles such as liposomes can also be used to introduce the non-viral vectors described above into recipient cells within the inoculated area. Such transfection vehicles are known by one skilled within the art.
  • the methods and compositions of the present invention are useful to regulate the proliferation and/or to prolong the survival of neurons, and in particular to stimulate proliferation and/or promote survival of neurons that are injured or degenerating, for example from diseases such as Alzheimer's, or to prolong survival of transplanted neurons.
  • the methods and compositions are also useful to inhibit proliferation of neuronal tumors.
  • type A and or type B receptors In neurons that express stimulatory peptide receptors, such as type A and or type B receptors, administration of compounds such as ANPs, will result in stimulation of proliferation or enhanced survival of the neurons, which can be used to treat, for example, nerve injury or neurodegenerative disease.
  • type B receptors predominate, such that administration of compounds such as ANPs that interact so as to stimulate B receptors should result in stimulation of proliferation or enhanced survival of the neurons present in that region.
  • administering In neurons that express type C receptors, such as tumors, administration of the ANP compositions of the invention will result in inhibition of proliferation and/or survival of neurons via response of the type C receptors. Such inhibition can lead to tumor regression.
  • ANPs that express multiple receptors that are inhibitory and stimulatory, for example cells that express A, B, and C and C-like (e.g. NNPR) peptide receptors, such as the neuroblastoma cell experiments described in the Example, infra
  • administration of ANPs at high doses e.g. in the range of 10 nM to 1 ⁇ M will result in inhibition of proliferation of the tumor cells as a result of response of the C and C-like receptors.
  • Administration of low doses of ANPs e.g. in the subnanomolar range (1 picomole to 1 nM) in such cells, will result in stimulation of proliferation or enhanced survival of such cells via the response of A and B receptors.
  • the methods of the invention include the administration of compounds to block endogenous natriuretic peptides in vivo in order to prevent binding to type A or B receptors on cells where such binding results in increased proliferation of tumor cells.
  • agents include antibodies against natriuretic peptides, for example anti-ANP antibodies and anti- PHI-related neuropeptides.
  • the invention provides methods for diagnosing in a subject, e.g., an animal or human subject, a cancer associated with the presence an NPR receptor.
  • the method comprises quantitatively determining the NPR receptor in the sample (e.g., cell or biological fluid sample) using any one or combination of antibodies reactive with NPR. Then the amount of NPR receptor so determined can be compared with the amount in a sample from a normal subject. The presence of a measurably different amount (i.e., the amount of NPR receptor in the test sample exceeds the number from a normal sample) in the samples suggesting the presence of the neuronal cancer. The progress of the tumor can be monitored, as can efficacy of treatment using such methods.
  • antibodies against NPR receptors can be used in diagnostic kits comprising an antibody that recognizes and binds NPR receptor; and a conjugate of a detectable label and a specific binding partner of the anti-NPR antibody.
  • the label includes, but is not limited to, enzymes, radiolabels, chromophores and fluorophores.
  • antibodies reactive with a NPR receptor of the invention may be particularly useful in diagnostic assays, imaging methodologies, and therapeutic methods in the management of neuronal cancer.
  • Diagnostic assays generally comprise one or more monoclonal antibodies capable of recognizing and binding NPR, and include various immunological assay formats well known in the art, including but not limited to various types of precipitation, agglutination, complement fixation, radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofiuorescent assays (ELIFA) (H. Liu et al. Cancer Research 58: 4055-4060 (1998), immunohistochemical analysis and the like.
  • immunological imaging methods capable of detecting neuronal cancer can be used, including but limited to radioscintigraphic imaging methods using labeled NPR antibodies.
  • Such assays may be clinically useful in the detection, monitoring, and prognosis of neuronal cancer.
  • NPR receptors may be detected in tumor biopsies to assess in staging and prognosis.
  • Antibodies against NPR can also be used therapeutically to target neuronal cancer cells when used alone or conjugated to a radioisotope or toxins.
  • This example demonstrates the proliferative action of natriuretic peptides on neuroblastoma Neuro2a cells.
  • Neuro2a cells (ATCC, Rockville, MD) were maintained in 75 cm flasks (Falcon, South Dakota) in 20 ml of Dulbecco's Modified Eagle Medium (DMEM) (Cellbio/Fisher). Medium was supplemented with 8% fetal bovine serum (FBS) (Gibco- BRL/Life Technology, Gaithersburg, MD) and antibiotics (penicillin/streptomycin) under a 5% CO / 95% air controlled atmosphere at 37° C. The medium was changed every 3 days. Passages were performed after trypsinization (0.05% trypsin /0.53 mM EDTA, Gibco- BRL/life technology Gaithersburg, MD).
  • FBS fetal bovine serum
  • antibiotics penicillin/streptomycin
  • NPRA/NPRB antagonist HS- 142-1 was kindly provided by Kyowa Hakko Kogyo Co., Shizuoka, Japan.
  • Peptides (desANP 4-23 obtained from Sigma Chemical Co. (St. Louis, MO), ANP, CNP, and VIP from Sigma, St. Louis, MO) were added, and then lh later 3 H-thymidine (1 :Ci/well) was added.
  • H-thymidine inco ⁇ oration was determined as previously described (Lelievre et al., J. Biol. Chem. 31 :19685-19690 (1998)) using TCA precipitation.
  • Radioiodinated PHJ binding experiments were performed on intact cells in suspension, using a slightly different procedure to increased sensitivity.
  • Nonconfluent cultures were harvested by incubation for 5 min at 37°C in a phosphate buffer (0.05M, pH 7.4) containing 0.53 mM EDTA. Cells were then quickly centrifuged, pellets were reconstituted in the binding buffer containing 35,000 cpm of I-PHI and specified concentrations of the unlabeled ligands, and then cells, were incubated under shaking.
  • Cyrlir MP and GMP measurements Cells (80,000/well) were cultured for 3 days in 24- well plates. Medium was replaced with serum-free medium with or without 10 ⁇ M isobutylmethylxanthine (IBMX) or 2 ⁇ M forskolin (Sigma, St. Louis, MO). After incubation for 15 min at 37°C, peptides were added and incubated further for 15 min at 37°C. Cells were lysed in 6% TCA solution and radioimmunoassays were performed following recommendations of the manufacturer (Dupont-NEN Life Science Products).
  • IBMX isobutylmethylxanthine
  • 2 ⁇ M forskolin Sigma, St. Louis, MO
  • Intrarp.llulnr calcium fluorometry Cells were cultured for 3 days on glass coverslips until 80% confluency was reached. Then cells were incubated in culture medium for 2h at room temperature in the presence of 5 ⁇ M fura-2/AM. Cells were rinsed twice in HBSS medium containing 0.1% BSA, MgSO , CaCl 2 , NaHCO 3 and MgCh (Gibco-BRL/Life Technology, Gaithersburg, MD). Measurements were performed at 30°C for 300 s on a Hitachi F2000 fluorescence spectrophotometer.
  • Neural tubes were then transferred into a dissociation solution (CO 2 independent medium supplemented with 1 mg/ml of trypsin and 10 ⁇ g/ml of DNAse) and incubated at 37°C for 12 min. Enzymic digestion was stopped by transferring the neural tube into a stop buffer (CO2 independent medium containing 5% serum). In this buffer, neural tubes were dissected. First the tube (not closed at E10 at the level of the hindbrain) was incised to form a layer of tissue, then the two layers of tissues constituting the tube (neuroepithelial cell layer inside and mesoderm layer outside) were separated using fine tweezers.
  • a dissociation solution CO 2 independent medium supplemented with 1 mg/ml of trypsin and 10 ⁇ g/ml of DNAse
  • the mesoderm was discarded, while the neuroepithelial cell layer was transferred into a washing buffer (Hank's solution, Gibco, Gaithersburg, MD). After spinning down the layers, the washing buffer was replaced by a trypsin solution for a 10 min incubation at 37°C, and digestion was stopped by addition of 10% FCS (fetal calf serum). The cell suspension was spun down again and the trypsin solution was washed twice with 10 ml of culture medium.
  • a washing buffer Horco, Gibco, Gaithersburg, MD
  • FCS fetal calf serum
  • the cells were then plated out in 5 ml of culture medium (Neurobasal medium from Gibco, Gaithersburg, MD) containing Penicillin/streptomycin, IX N2 supplement (Gibco, Gaithersburg, MD) and 10 ng/ml of bFGF (basic Fibroblast growth factor) (Sigma, St. Louis, MO). Cells were cultured overnight and dividing cells (pseudoganglions) were subcultured for PCR as described below.
  • culture medium Neuroblasts
  • RT-PCR- PolyA + -selected mRNAs from Neuro2a cells or mouse tissues were reverse- transcribed into cDNA and amplified by polymerase chain reaction (PCR), using the GeneAmp kit supplied by Perkin Elmer. Primers were designed using the Primer3 software, from mouse or rat natriuretic-receptor sequences published in the NCBI database, and were synthesized by BRL-Gibco.
  • the initial set of selected sense primers were 5'- ATTTGTGGGAGCTTGTACCG-3', 5'-GTGTACCCTGCTGCCTCTGT-3 and 5'- CTTCCAGGTGGCCTACGAA-3' and antisense primers were 5'-GGCAATTTCC TGAAGGATGA-3', 5'-CCGCAGATATACACAATGCG-3' and 5'-GGCACACATGAT CACCACTC-3' for natriuretic receptor subtypes A, B, and C, respectively. These were designed to generate PCR fragments of 389, 379 and 492 bp, corresponding to nucleotides 1790-2179, 376-755 and 279-771 for natriuretic receptor subtypes A, B, and C respectively.
  • Amplifications were carried out for 35 cycles of denaturation (94°C, 50 s), annealing (54°C, 45 s) and extension (72°C, 45 s). PCR was finished by a step of 5 min at 72°C. Single products of the expected size were amplified from Neuro2a cell RNA (corresponding to the receptor subtypes A and B), or from mouse kidney (receptor subtype C).
  • PCR products were subcloned into PCR2.1 vector using a TA cloning kit (Invitrogen, San Diego, CA), and sequenced to confirm their identity.
  • CTTCCAGGTGGCCTACGAA-3', 0MPRC2+, 5'-CTGGACGACATAGTGCGCTA-3'; OMPRC3- 5'-GGCACACATGATCACCACTC-3' (located in positions 290-309, 714-734 and 771-751, respectively) were the same as previously used to amplify the NPRC from mouse kidney.
  • Consensus primers were also designed I highly conserved regions between mouse, human, bovine and eel NPRC sequences. These oligonucleotides were named OPRCX1+ (5'TGAGGACAGCG AAACCTGAGTT-3'), OPRCX2+ (5'-
  • PCR was finished by a step of 5 min. at 72°C. Two different concentrations of MgCl (2 and 3 mM) were tested for each set of primers.
  • RNA from mouse brain and polyA-selected mRNA from mouse Neuro2a neuroblastoma cells, kidney and spleen tissues were loaded at the concentration of 15 ⁇ g/lane on 0.8% agarose 2% formaldehyde MOPS gel. After transfer to nylon membranes (Magna, MSI), blots were prehybridized overnight and then hybridized for 8 hours at 45 °C with cloned natriuretic receptor cDNA probes originally obtained from PCR experiments. EcoRI -generated probes were labeled by random inco ⁇ oration of 32 P-dCTP (Random prime kit from Gibco-BRL, Gaithersburg, MD). After 3 washes for 20 min at 54°C in 0.2X SSC buffer containing 0.1 % SDS, blots were exposed for 3 days and signals detected with a Phosphorimager (Molecular Dynamics).
  • Phosphorimager Molecular Dynamics
  • natriuretic peptides were unaffected by O-phenanthrolin and bacitracin, which have been shown to potently inhibit endopeptidase activities that cleave natriuretic peptides in other neuroblastoma cells (Delporte C. et al., Eur J Pharmacol, 227:247-56 (1992)), indicating that the actions of ANP analogs were not due to ANP degradation products.
  • PK protein kinase
  • PKA and PKC inhibitors did not significantly alter the inhibitory actions of any of the natriuretic analogs tested ( Figures IB and IC, respectively).
  • PD98059 completely inhibited the anti- proliferative actions of ANP, CNP and desANP 4-23 ( Figure ID), resulting in stimulation rather than inhibition of proliferation at ANP and CNP concentrations of 10 nM and above
  • PKG inhibitor completely blocked the ANP and CNP-induced stimulatory effects, and enhanced the inhibitory effects of ANP peptides ( Figure IE).
  • NPRC-specific agonist desANP 4-23 suggested that these cells express a type C receptor coupled to growth inhibition. Although lower concentrations of ANP and CNP slightly stimulated proliferation via GC receptors, higher concentrations (10 nM and greater) inhibited growth, perhaps due to over-riding action on a type C (non GC) receptor. The possibility that a type C receptor mediated the growth-inhibitory actions was supported by the fact that antiproliferative effect of each natriuretic peptide was insensitive to PKG blockade. Instead, all inhibitory actions were selectively sensitive to MAP kinase pathway blockade.
  • NPRA or NPRB could couple to an alternative signaling pathway in the presence of higher concentrations of natriuretic peptides.
  • DNA synthesis was determined in cells incubated with antiproliferative concentrations of natriuretic peptides in the presence and absence of the NPRA NPRB-selective antagonist HS- 142-1 (Matsuda Y., Humana Press Inc, Totowa NJ (Samson WK and Levin ER eds), chapt. 17, pp. 289-307 (1997)) ( Figure 2).
  • HS- 142-1 had a only a negligible effect on DNA synthesis in untreated cells indicating Neuro2a cells produce little, if any, natriuretic peptides capable of interacting with NPRA or NPRB under these conditions.
  • IC 50 values gave the following pharmacological profile: desANP 4-2 3 ⁇ CNP ⁇ PACAP- 38 ⁇ VtP ⁇ PHKANP «PACAP-27. Approximately 65% of ANP binding was competitively inhibited by the selective NPRA/NPRB inhibitor HS 142-1, with an IC50 of about 7 ⁇ g/ml
  • ANP, desANP -23 was still able to specifically displace I-ANP binding (about 35% of total binding in the absence of HS 142-1), with an IC50 of about 22 "3.5 pM (Figure 4B).
  • Natriuretic peptide-induced changes in cGMP levels were measured in Neuro2a cells in the presence of 10 ⁇ M IBMX to inhibit phosphodiesterase activity.
  • ANP and CNP potently triggered up to a 6-fold increase of cGMP levels, whereas desANP 4- 2 3 and PHI did not produce any measurable change ( Figure 5).
  • PHI at 50 nM a concentration that did not increase cGMP or cAMP, did not alter the ANP-induced cGMP elevation.
  • Type C receptors have been shown to couple to adenylate cyclase inhibition and calcium influx in other systems (Hirata M. et al., Biochim Biophys Acta, 1010: 346-351 (1989); Maack T. et al., Science, 223:675-678 (1987)).
  • peptide-induced changes in cAMP levels were measured in the presence of 2 ⁇ M forskolin. None of the ANP analogs effected cAMP levels under these conditions.
  • PHJ induced activation only at concentrations over 100 nM.
  • RT-PCR and Northern blot analysis were used to detect the three natriuretic receptor genes in Neuro2a neuroblastoma cells.
  • Northern blot analysis with 15 ⁇ g polyA-selected RNA from Neuro 2a cells confirmed expression of NPRA and NPRB genes, but failed to visualize the expression of NPRC gene in Neuro2a cells ( Figure 7).
  • Internal positive controls (kidney, spleen and brain RNA) confirmed specificity of hybridizations.
  • natriuretic peptides regulate the proliferation of mouse Neuro2a neuroblastoma cells via specific receptor subtypes and signaling pathways.
  • H-thymidine inco ⁇ oration was conducted over a 5 hour- treatment period with the different ANP analogs to determine if these cells expressed functional natriuretic receptors capable of regulating growth.
  • Low concentrations of ANP and CNP were found to cause a slight increase in DNA synthesis that was sensitive to PKG blockade, indicative of action on NPRA and/or NPRB (GC) ("type C”) natriuretic receptors.
  • radioligand binding studies demonstrated that approximately one third of the total 5 I-ANP binding sites were insensitive to HS 142-1, and that desANP 4- 2 3 displaced I-ANP binding completely, and with high affinity.
  • the action of desANP -23 was sensitive to inhibition of MEK1/2, indicating that both of these peptides inhibit growth via an ANP signaling pathway (Prins et al., J. Biol. Chem. 271:14156-14162 (1996)).
  • Radioligand binding studies also demonstrated the ability of PHI to displace the I-ANP binding.
  • This example describes the effects of natriuretic peptides on the proliferation of human and rodent neuroblastoma cell lines.
  • Neuro2a neuroblastoma cells were obtained from American Type Tissue Collection (Manassas, VA). SK-N-SH neuroblastoma subclones SHIN and SY-5Y were obtained from Dr. June Biedler (Sloan Kettering Cancer Institute, Rye, NY). NG108 neuroblastoma/glioma hybrid cells were obtained from Dr. Chris Evans, UCLA). All cell lines were maintained in 75 cm flasks (Falcon) in 20 ml of Dulbecco's Modified Eagle Medium (DMEM) (Cellbio/Fisher).
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • antibiotics penicillin/streptomycin
  • H-thymidine (1 uCi/well) was added lh later. Four hours later, cells were harvested and H-thymidine inco ⁇ oration determined as previously described (Lelievre V, et al., (1998), J Biol Chem, 273: 19685-19690). Cyclic AMP and GMP measurements
  • Cells (80,000/well) were cultured for 3 days in 24-well plates. Medium was replaced with serum-free medium with or without 10 mM isobutylmethylxanthine (IBMX) or 10 ⁇ M forskolin (Sigma, St. Louis, MO). After incubation for 15 min at 37°C, peptides were added and incubated further for 15 min at 37°C. Cells were lysed in 6% TCA solution and radioimmunoassays were performed following recommendations of the manufacturer (Dupont-NEN).
  • IBMX isobutylmethylxanthine
  • 10 ⁇ M forskolin Sigma, St. Louis, MO
  • Cells were cultured for three days on glass coverslips until 80% confluence was reached. Cells were then incubated in culture medium for 2h at room temperature in the presence of 5 ⁇ M fura-2/AM. Cells were rinsed twice in HBSS medium containing 0.1%BSA, MgSO 4 , CaCk, NaHC0 3 and MgCh (Gibco-BRL / Life Technology, Gaithursburg, MD). Intracellular calcium measurement was performed at 30°C for 300 s on a Hitachi F2000 fluorescence spectrophotometer.
  • 125 I-ANP (2200 Ci/mmol) was obtained from Dupont/NEN. Binding experiments were conducted on suspended cells in eppendorf tubes (800,000 cells/ml) in binding medium containing 35,000 cpm of I-ANP and the specified concentrations of competitive analogs. Incubation was performed at 4°C under gentle agitation. Rinses were performed and bound radioactivity measurements determined as previously described (Lelievre V, et al., (1998a), J Biol Chem, 273: 19685-19690).
  • Neuro2a cells were cultured in 8 flasks (75 cm ) and harvested at 90 % confluency with 0.05 % trypsin 0.02 % EDTA. Trypsin was neutralized with the tissue culture medium (containing 8% serum), cells were centrifuged and then rinsed with phosphate-buffered saline (PBS). Subsequent isolation of polyA-selected mRNA was carried out as described (Lelievre V, et al., (1998a), J Biol Chem, 273: 19685-19690).
  • Northern and RT-PCR analyses Total RNA from mouse brain and polyA-selected mRNA from mouse Neuro2a neuroblastoma cells, kidney and spleen tissues were loaded (15 ⁇ g/lane) on a 0.8% agarose 2% formaldehyde MOPS gel (Lelievre V, et al., (199 a), J Biol Chem, 273: 19685-19690; Waschek JA, et al., (1998) Proc Natl Acad Sci USA, 95: 9602- 9607).
  • blots were prehybridized overnight and then hybridized as described (Lelievre V, et al., (1998a), J Biol Chem, 273: 19685-19690) for eight hours at 45°C.
  • Natriuretic receptor cDNAs were obtained by RT- PCR experiments performed on mouse kidney RNA. RT-PCR-generated products were cloned into PCR-IJ vector (InVitrogen) and sequenced to confirm identity. EcoRI-excised cDNA inserts were labeled by random inco ⁇ oration of P-dCTP (Random primers kit, Gibco-BRL, Gaithursburg, MD). After three washes for 20 min at 54°C in 0.2X SSC buffer containing 0.1 % SDS, blots were exposed for three days and signals detected with a Phosphorimager (Molecular Dynamics).
  • FIG. 10B- D In all other neuroblastoma cell lines, a biphasic action of ANP and CNP was observed (Figure 10B- D). ANP and CNP slightly but significantly stimulated proliferation in all of these cell lines at subnanomolar concentrations, but inhibited cell proliferation at higher doses. Treatment with desANP -2 3 did not stimulate proliferation at any concentration but inhibited growth beginning at 0.1 nM. Stimulatory and inhibitory effects of natriuretic peptides were unaffected by O-phenanthrolin and bacitracin, which have been shown to potently inhibit endopeptidase activities that cleave natriuretic peptides in other neuroblastoma cells (Delporte C, et al., (1992). Eur J Pharmacol, 227:247-56). This indicates that the actions of natriuretic analogs were not likely due to degradation products of natriuretic peptides.
  • natriuretic peptide actions were studied in the presence and absence of various protein kinase (PK) inhibitors.
  • PK protein kinase
  • NG108 and Neuro2a cells were selected for these studies.
  • Rp-8- pCTP-cGMPS (20 uM), a protein kinase G (PKG) inhibitor (Zhuo M, et al., (1994), Nature, 368: 635-639). Cells were stimulated for 5 hr with increasing concentrations of natriuretic peptides in the presence of the protein kinase G inhibitor Rp-8-pCTP-cGMPS (15 ⁇ M).
  • the MEK1/2 kinase inhibitor PD98059 (20 ⁇ M) significantly decreased the basal rate of proliferation of NG108 cells, but did not block the induction of proliferation by ANP or CNP ( Figure 12A). The same was true in Neuro2a cells ( Figure 12B). Cells were stimulated for 5 hr with increasing concentrations of natriuretic peptides in the presence of MEK1/2 inhibitor PD98059 (30 ⁇ M). However, PD98059 completely abolished the growth inhibitory actions of higher doses of ANP, CNP and desANP 4- 2 3 in Neuro2a cells.
  • natriuretic peptides appear to require the basal activity of a MEK1/2 pathway.
  • Inhibitors of PKA (H89, 20 ⁇ M) (Chijiwa T, et al., (1990) JBiol Chem, 265, 5267-5272) and PKC (GF109203X, 10 ⁇ M) (Toullec D, et al., (1991) J Biol Chem, 266, 15771-15781) did not significantly alter the inhibitory actions of any of the natriuretic analogs.
  • NPR-A and/or NPR-B switch to
  • NPR-B DNA synthesis was determined in Neuro2a cells incubated with 10 nM and 1 ⁇ M natriuretic peptides in the presence or absence of the NPR-A/NPR-B-selective antagonist HS- 142-1 (Matsuda Y (1997) Contemporary Endocrinology: natriuretic peptides in health and disease (Samson WK and Levin ER eds) chapt. 17, pp. 289-307,
  • NPR-C (the only known target for desANP 4- 2 3 ) has been shown in some systems to couple to adenylyl cyclase inhibition and calcium influx (Hirata M, et al., (1989) Biochim Biophys Acta, 1010: 346- 351; Maack T, et al., (1987) Science, 238: 675-678).
  • peptide-induced changes in cAMP levels were measured in the presence of 10 ⁇ M forskolin. None of the ANP analogs affected cAMP levels under these conditions.
  • I-ANP binding was determined on NG108 and Neuro2a cells in the presence and absence of increasing concentrations of ANP, CNP and ANP 4- 2 3 .
  • displacement curves Figure 16A
  • derived IC50s Table II
  • Suspended cells were incubated 4°C for 150 min.
  • Data displayed were the mean ⁇ SEM of 2 independent experiments each performed in triplicate.
  • Graphs and curve fittings were computerized using Graphprism software. Hill values were near unity for all analogs, suggesting ligand/receptor interactions occurred on an apparent single 125 I-ANP binding site.
  • the observed analog rank potency suggests that the receptor on NG108 cells is NPR-A (Nakao K, et al., (1992) J Hypertension, 10: 1111-1114).
  • Table II shows the displacement of ANP radioligand by unlabelled analogs in Neuro2a and NG108 cells. Displacement parameters were extracted from curves given in Figure 16.
  • Northern blot analysis was used to detect the three known natriuretic receptor mRNAs in Neuro2a cells.
  • Lanes contained 15 ⁇ g of polyA-selected RNA, extracted from Neuro-2a, kidney, spleen and 15 ⁇ g of total RNA from brain, respectively.
  • Hybridizations were performed overnight at 45C with the corresponding probes as described in Methods. Ribosomal subunits 28 and 18S were used as size markers.
  • Hybridization to polyA- selected RNA revealed expression of NPR-A and NPR-B genes in Neuro 2a cells, but failed to show the presence of an NPR-C mRNA in Neuro2a cells ( Figure 18). Internal positive controls (kidney, spleen and brain RNA) confirmed specificity of hybridizations.
  • natriuretic peptides regulate the proliferation of neuroblastoma cell lines in a cell-specific manner.
  • ANP and CNP induced purely a dose-depended increase in thymidine inco ⁇ oration by a mechanism that involved cGMP-dependent PKG.
  • Growth stimulatory effects were also observed in SK-N- SH subclones and Neuro2a cells at low concentrations of natriuretic peptides. However, at higher peptide concentrations, the growth stimulatory effects in these cells were apparently overridden by a growth-inhibitory mechanism. This inhibitory effect was sensitive to the MEK1/2 inhibitor PD98059.
  • NPR-A or NPR-B receptors contain a GC domain in the intracellular portion of the receptor that is classically activated by agonist binding.
  • ANP was significantly more potent than CNP in inducing proliferation and displacing 125 I-bmding in NG108 cells, suggests that the primary receptor subtype expressed was NPR-A.
  • Natriuretic peptide stimulation of proliferation via cGMP induction has been observed in other cell types, for example chick embryonic cardiomyocytes (Koide M, et al, (1996) Differentiation, 61: 1-11).
  • the GC pathway also appears to mediate the stimulatory effects of natriuretic peptides on bone growth (Yasoda A, et al., (1998) J. Biol Chem, 273: 11695-11700).
  • the actions of natriuretic peptides on the growth SK-N-SH subclones and Neuro 2a cells were more complex.
  • Low concentrations of ANP and CNP induced an increase in DNA synthesis that was sensitive to PKG blockade, again indicative of action on NPR-A and/or NPR-B (GC) natriuretic receptors.
  • higher concentrations of ANP and CNP inhibited proliferation in a manner that was insensitive to PKG blockade.
  • natriuretic peptides act downstream of a growth- stimulatory MEK1/2 pathway that is constitutively-active in these cells under the study conditions.
  • growth-inhibitory concentrations of natriuretic peptides act via MEK 112 induction.
  • these receptors might switch to a non-GC growth-inhibitory signaling pathway.
  • This possibility was tested by treating cells with the NPR-A/NPR-B-specific inhibitor HS 142-1. This reagent did not prevent the growth-inhibitory effects, suggesting that neither NPR-A nor NPR-B was involved in the antiproliferative actions.
  • An alternative possibility was that the growth inhibitory actions are mediated by another receptor. To support this possibility, radioligand-binding studies
  • NPR-C type C "clearance” receptor
  • NPR-C is expressed in Neuro2a cells, but at levels below detection by Northern analysis, and 2) a receptor other than NPR-C that binds both natural natriuretic peptides and desANP 4 .2 3 mediates the growth inhibitory actions.
  • a normal NPR-C as well as an NPR-C-like receptor was recently cloned from eel.
  • the data also suggests potential proliferative and antiproliferative actions of natriuretic peptides on neuroblastoma tumor growth. If the opposing actions of natriuretic peptides on neuroblastoma cell proliferation are mediated by different receptors, then the balance of these receptors (i.e. the relative amounts of and types of receptors on each cell) might influence the overall growth of these cells in response to endogenous natriuretic peptides.
  • the amount and/or activity of NPR-A receptors might be increased while decreasing the amount and/or activity of NPR-B receptors such as by using antisense oligonucleotides complementary to a NPR-A receptor or NPR-B receptor to inhibit the expression of the receptor,.
  • ligands that specifically antagonize NPR-A and/or NPR-B receptors, or that stimulate non-GC growth receptors involved in growth inhibition can be used to alter the balance and thus activity of these receptors.
  • This example describes that gene expression, for natriuretic peptides and their receptors, was detected in the discrete regions of the embryonic brain and developing blood vessels at the onset of neurogenesis.
  • natriuretic peptides play important roles in the development of certain organ systems
  • the recent reports of natriuretic transgenic and knockout mice exhibiting severe skeletal defects have added strong evidence that natriuretic peptides can act in growth-related capacities.
  • natriuretic peptides have been shown to potently regulate the proliferation of cultured neuronal and glial cells, and regulate the proliferation and recruitment of blood vessel cell components.
  • PACAP pituitary adenylate cyclase activating peptide
  • PACAP-related peptides might in certain cases act on receptors that classically mediate the action of a seemingly unrelated family of peptides, the natriuretic factors (Murthy KS, et al., (1998) Am J Physiol, 275 :C 1409- 16). Because the proliferative action of PACAP and related peptides in neuroblastoma cells could not be fully explained by the presence of known PACAP receptors, the expression of natriuretic receptors coupled to proliferation was examined. Neuroblastoma cells were found to express functional NPRAs and NPRBs, which were positively coupled to growth via guanylate cyclase. NPRC or NPRC-like receptors were also present, but were negatively coupled to growth via MAP-kinase inhibition.
  • natriuretic peptides have important roles in nervous system development. Embryonic expression of natriuretic peptides and their receptors in the nervous system and associated blood vessels
  • mice were conducted on mice at embryonic day (E) 10.5, and at E12.5 (approximately equivalent to El 1.5 and E13.5 in rats, respectively, and E0.5 is the morning after fertilization) using in situ hybridization.
  • E embryonic day
  • E12.5 approximately equivalent to El 1.5 and E13.5 in rats, respectively, and E0.5 is the morning after fertilization
  • the central nervous system consisted primarily of a layer of proliferating cells (folded into a tube, but not fully closed at the anterior end).
  • vascular invasion of the CNS has just begun (Herken R, et al., (1989) J Anat, 164:85-92; Bauer HC, et al., (1993) Brain Res Dev Brain Res., 75:269-78; Conradi NG and P Sourander (1980; Acta Neuropathol
  • NPRC gene expression (using a P-labeled mouse NPRC riboprobe (Waschek JA, et al., (1998) Proc Natl Acad Sci USA, 95:9602-7)) could clearly be detected in the area surrounding the neural tube, presumably the perineural vascular plexus ( Figure 19A), major arteries ( Figure 19 B, C, and D) and to a lesser extent in veins. Expression was also observed in the notochord ( Figure 19 C and D), a structure well known to produce factors (such as sonic hedgehog) responsible for dorsal/ventral pattering of neurons and glia in the neural tube. Expression was also observed in the heart and surface ectoderm.
  • NPRC gene expression continued to be observed in the perineural vascular plexus and surface ectoderm ( Figure 20 A and B), and in several peripheral ganglia (dorsal root ganglia shown in Figure 20 C and D; trigeminal ganglia in Figure 20 E and F). Analyses of sagittal sections in the area of the trigeminal ganglia clearly revealed expression in the trigeminal, maxillary, and mandibular nerves, very likely in the Schwann cells ( Figure 20 E and F).
  • NPRC neuropeptide derived neuropeptide
  • oligodendrocytes precursors are relevant as the oligodendrocyte cess are responsible for re-myelinating nerves, and are implicated in certain diseases, such as multiple sclerosis.
  • NPRB was consistently expressed at low levels on cells just outside the VZ of the hindbrain, presumably corresponding to early postmitotic neurons (Figure 21 A and B). Much higher gene expression was observed in many developing peripheral ganglia (trigeminal ganglia in Figure 21 A and B, and dorsal root ganglia in Figure 21 C). No expression was detected in vascular tissue, or in any areas outside of the nervous system. In contrast, no NPRA gene expression was observed within the brain or in any ganglia, while a very low level of expression was observed at E10.5 and E12.5 in blood vessels of the head, and in the surface ectoderm.
  • natriuretic peptide receptor gene expression was examined (Waschek JA, et al. (1998). Proc Natl Acad Sci USA 95:9602-7). Cells were isolated from E10.5 mouse neural tubes and cultured as described (Waschek JA, et al., (1998) Proc Natl Acad Sci USA, 95:9602-7). Peptides were added at the indicated concentrations.
  • Type C receptor gene was also expressed in the notochord, suggesting a role of this receptor in dorsal/ventral patterning of the nervous system.
  • a low level of Type B receptor gene transcript appeared in the few postmitotic neurons just outside of the proliferating cells in the ventricular zone.
  • Type A receptor transcripts were not observed anywhere in the neural tube or developing ganglia. However, abundant type A and C receptor gene transcripts were detected in surrounding blood vessels and in the heart. At El 2.5, type C receptor transcripts again were detected in the lamina terminalis, in the trigeminal, VEH, TX and dorsal root ganglia and notochord, but also in the roof plate of the neural tube.
  • the type C receptor gene was also very clearly expressed in narrow stripes in the ventricular zone on each side of the floor plate in the spinal cord.
  • the telencephalon a region in the rat which has shown a high degree of specific binding with the characteristics of a clearance- like ANP receptor (Brown et al., and Zorad et al., supra), notably lacked known type C receptor gene expression.
  • the autoradiography indicated that significant type C-like receptor binding was present in the proliferative zones of the telencephalon, despite the absence of gene expression for known type C receptor.
  • natriuretic peptide receptor binding sites were present in the juxtaventricular zone of the telencephalon in E14 and E17 rats (Brown et al., and Zorad et al., supra). These sites were characterized by radioligand displacement using several ANP analogues and displayed a type-C like nature (for example, binding was fully displaced by desANP -23 ).
  • natriuretic peptide receptors were expressed in the embryonic nervous system and associated blood vessels were confirmed. Localized receptor gene expression was detected at stages earlier than that previously reported, at El 0.5 (near the time of onset of neurogenesis and brain vascularization).
  • the primary receptor subtype on developing blood vessels, Schwann cells, ganglion satellite cells, and presumed oligodendrocyte precursors was found to be NPRC.
  • the subtype on newly differentiating neurons was found to be NPRB.
  • the expression of NPRC in Schwann and ganglionic satellite cells may be significant in brain vascularization, because glia cells are thought to be important for angiogenesis in neural tissue and in the formation of the blood-brain and blood-nerve barriers.
  • the NPRC gene was also shown to be expressed in the roof plate and notochord. These structures play important roles in dorsal/ventral patterning and axonal guidance in the CNS. Gene expression for the ligand CNP was detected at high levels in the VZ in the hindbrain and spinal cord, providing an endogenous source of natriuretic ligand within the developing brain. The proliferation of El 0.5 neural tube neuroblasts in culture was found to be potently inhibited by CNP.
  • natriuretic peptides produced either in the heart or brain, regulate nervous system development. They may do so by acting directly on developing neurons and glia, and by acting on cells involved in the developing brain vasculature, including glia, endothelial cells, pericytes, and VSMCs.
  • This Example describes the ability of natriuretic peptides such as ANP and PHJ-related neuropeptides to act as trophic factors (i.e. act on survival) of motor neurons after facial nerve axotomy.
  • This model is widely recognized for evaluating agent that can prevent motor neuron cell death in vivo.
  • Price et al. Ciba Found. Symp. 196:3-13 (1996); Kreutzberg, Acta Neurochir. Suppl (Wien) 66:103-6 (1996); Raivich et al., Keio. J. Med. 45:239-247 (1996); deLapeyriere, Curr. Opin. Genet. Dev.
  • Facial nerve axotomy is performed in neonatal rats as described in the literature.
  • facial nerve axotomy results in massive motor neuron death (greater than 80%) within four days. Briefly, animals are anesthetized, the right facial nerve is exposed and a cut is made at the point where the nerve exits from the stylomastoid foramen. The left (contralateral) side serves as a control. In some of these animals, sham operations are also performed on the right side. Other controls include right side sham-operated animals and normal animals. Animals are axotomized at three ages, postnatal day 1 , postnatal day 5 and adult (10 weeks). Changes in the predicted responses in the facial motor nucleus (microglia activation, chromatolysis, etc) are observed after administration of VTP, PHJ, and ANP cDNAs (in the sense or antisense orientation as appropriate).
  • VTP, PHI and ANP are delivered to facial motor neurons in Wistar rats and or C57/BL6 mice using a retroviral delivery system to rescue dying motor neurons and to block the action of endogenous peptides using receptor antagonists.
  • the peptides are delivered to axotomized facial motor neurons by injecting the virus into the rat facial muscle, for retrograde transportation to the facial motor neurons.
  • the encoded gene products are expressed relatively specifically in the facial motor neurons with minimal or no perturbation of either the injury site or the facial motor nucleus.
  • a two-plasmid system is used to generate recombinant adenoviruses containing the VTP, PHI or ANP cDNA (Baumgartner and Shine, J. Neurosci.
  • the first plasmid, pJM17 contains the viral genome with a pBR322 variant (pBRX) inserted into the Ela region. This permits propagation in E. coli and prevents formation of active virus producing a first generation vector.
  • the second plasmid is the shuttle vector into which the mouse VTP, PHI or ANP cDNA is inserted. The two plasmids are co-transfected into 293 cells, which are then covered with a mixture of medium and agarose.
  • a homologous recombination event occurs between the two plasmids that result in the replacement of pBRX with VIP, PHI or ANP cDNA.
  • the recombinant vectors that result produce plaques on the culture plates. Plaques are picked and amplified for screening by PCR and large-scale preparation as described by Baumgartner and Shine, 1997 and 1998, supra.
  • the cDNA can be modified to optimize expression in such delivery systems.
  • the cDNA can be engineered to contain an optimal Kozak consensus sequence to increase expression.
  • Recombinant virus is injected into the rat facial muscle on postnatal day 1 rats.
  • the parent virus containing the ⁇ -galactosidase gene is infected.
  • the gene has been shown to be expressed in facial motor and trigeminal neurons after injection into the facial muscle (Baumgartner and Shine, 1997, supra).
  • Expression of VIP, PHI or ANP and ⁇ - galactosidase is monitored using immunohistochemistry and enzymatic histochemistry, respectively, using standard procedures.
  • the degree of axotomy-induced cell death after injection of virus is determined. On postnatal day 1 (24 hrs before axotomy), viral vectors containing cDNAs are injected into the left facial muscles of the cheek, lower lip and whisker pad on the side to be lesioned. Animals are sacrificed 48 and 96 hrs after surgery. Rats are anesthetized and perfused with 4% formaldehyde. The brain stem is dissected, post fixed, cryoprotected and sectioned across the region containing the facial motor nucleus. The degree of motor neuron death is assessed on ipsilateral and contralateral sides of the facial motor nucleus on every fifth section using cresyl violet staining. Only motor neurons with a clearly identifiable nucleus and nucleolus are counted. In between sections are used to confirm expression of recombinant proteins.
  • VTP, PHJ and/or ANP delay motor neuron death in axotomized animals. Moreover, these factors may enhance efficacy of classical neurotrophins by delaying neuronal death and enhancing trk expression.
  • VTP/PHI/ANP are delivered to motor neurons in axotomized adult rats using the delivery methods described in this Example, and the effects on chromatolysis or ChAT expression are determined.
  • adult BalbC mice are used because axotomy causes greater than 30% neuron cell death after one week in these animals (Ferri et al., J. Neurobiol. 34:1- 9 1998)).
  • VTP VTP
  • PHI ANP
  • ICV intracerebral ventricular
  • VTP, PHJ and/or ANP are delivered to axotomized facial neurons using a piece of gelfoam soaked in the factor placed at the lesion site, (de Bilbao and Dubois-Dauphin, Neuroreport 7:3051-3054 (1996)).
  • NPRC Xenopus natriuretic peptide type-C receptor
  • NPRC Xenopus natriuretic peptide type-C receptor
  • the data provided herein demonstrates that NPRC is coupled to signaling pathways that are commonly used to regulate cell growth and survival. Further, the action of peptides on NPRC is shown to modify the signaling of unrelated receptors, and thus these actions can affect proliferantion and/or survival indirectly.
  • natriuretic peptides play a key role in maintaining body fluid homeostasis. This action may be crucial for species that experience large environmental variations in salt concentration, for example, fish and amphibians.
  • This pair of primers (Life technologies, Gaithersburg, MD) was designed to generate fragments of 471, 447, 471 and 462 bp corresponding to nucleotides 1427-1868, 869-1330, 1807-1336, 967-1429 and 945-1399 for NPR-C from bovine, eel, human, mouse and rat, respectively.
  • PCR amplification was carried out for 35 cycles of denaturation (94C, 50s), annealing (48C, 45s and extension (72°C, 45s), using increasing concentrations of MgCh from 2 to 4 mM. A last extension at 72°C for 5min concluded the PCR method.
  • the Xenopus PCR-generated probe (450 bp) was radiolabelled with [alpha- 32 ⁇ P] dCTP random primer labeling kit (Life Technologie, Gaithersburg, MD). This probe was used to screen a Xenopus brain lambda Ziplox cDNA library (GibcoBRL, Gaithersburg, MD) provided by Dr. E. deRobertis (UCLA). Approximately 0.6 XlO plaques were screened at an initial density of 20,000 plaques/plate (10 cm bacterial plates) and transferred onto nitrocellulose membranes (MSI). Membranes were air-dried for 10 min. Phage plaques were gently lysed in 1.5 M NaCl /0.2M NaOH solution for 2 min.
  • the remaining 2 strongly positive clones (# 36 and 38) were once again diluted and plated to an approximate density of 15 clones per plate. The plates were then transfered and hybridized as above. Isolated phages from positive plaques were transformed into plasmid using the rapid excision procedures according to the manufacturer (GibcoBRL, Gaithersburg, MD). The two excised BlueScript plasmids were amplified in DHlObZL cells (GibcoBRL, Gaithersburg, MD). Restriction site analysis revealed insert sizes of 3 and 2.5 kb, respectively. Sequencing of these clones was performed in both directions.
  • the cDNA encoding XNPRC was isolated using double digestion with BamHl/Clal, and was inserted into the pCS2 vector. Plasmids were amplified in ToplO cells (InVitrogen) and linearized using Nsil endonuclease to obtain a template for in vitro transcription. Using 10 ⁇ g of DNA template, capped XNPRC mRNA was transcribed using Sp6 polymerase and a transciption kit from Promega. Capped messenger RNAs (C-mRNA) were purified with DNasel and subsequent phenol/chloroform extraction. Purified C- mRNA were reconstituted in RNAse-free water (Ambion) and frozen at -20 DC. Preparation of capped Xenopus PAC1 receptor mRNA was as described (Hu Z, et al. (2000) Endocrinol, 141 : 657-665).
  • oocytes Under stereomicroscope (Zeiss), oocytes were injected with aqueous solution of XNPR-C mRNA using a Nanoliter injector attached to a Kite micromanipulator (WPI). Injected oocytes were rinsed twice within SOS buffer, and kept for 4 days at 18°C. For binding assays, about 30ng of capped mRNA were injected per oocytes, whereas, only 15 ng of NPR-C or/and PAC-1 mRNAs were used for the transduction experiments.
  • WPI Kite micromanipulator
  • Injected oocytes were rinsed for 20 min in binding medium (SOS buffer containing 0.1 % BSA and a protease cocktail including O-phenanthrolin, bacitracin and PMSF). Each sample contained 8 oocytes.
  • samples were incubated in binding buffer containing increasing concentrations of 125 I-ANP (2200 Ci/mmol, NEN), in the presence (non specific) or absence (Total) of 10 ⁇ M of native ANP for 150 min at 4°C.
  • Oocytes were carefully rinsed twice with 2 ml of cold wash buffer (Binding medium containing 1 % BSA). Oocytes were transferred to 5 ml tubes and the bound radioactivity was quantified using a Gamma-counter (LKB).
  • LKB Gamma-counter
  • oocytes (8/sample) were incubated for 150 min at 4°C, in binding buffer containing ' /-ANP (70,000 cpm/sample) and increasing concentrations (from 0 to luM) of the specified analogs.
  • Rat and frog analogs were obtained from Sigma (St. Louis, MO) and Phoenix pharmaceuticals, respectively.
  • HS- 142-1 was generously provided by Dr Y. Matsuda (Tokyo Research Laboratories, Tokyo, Japan). Washes and radioactivity measurement were performed as indicated above.
  • Cyclic AMP production in stimulated oocytes was assessed using a RJA kit according to the manufacturer recommendations (Dupont-NEN). Double- injected oocytes (10/sample) with C-mRNAs encoding NPRC and PAC1 receptors were preincubated in IBMX alone or with 50nM PACAP-38, prior to addition of the specified peptides. Cyclic AMP isolation and measurements were performed as described above.
  • a DNA fragment of 450 bp was amplified and cloned. This DNA fragment displayed a sequence with high homology to published NPR-C sequences and those available in the NCBI database.
  • a lambda phage cDNA library was prepared and screened. Fifty plates containing about 20,000 plaques/plate were analyzed. Among the four positive plaques observed after the first round of screening, two of them were found to be negative after the second screening. To isolate unique phage clones from the remaining plaques, a last round of screening was performed, where all the plaques strongly hybridized with the radiolabeled probe. Lambda phages were isolated from these plaques, and were transformed into Bluescript plasmid using a Ziplox rapid excision method (GibcoBRL, Gaithersburg, MD).
  • a hydrophobic plot showed a unique region of hydrophobic residues at C-terminal end of the molecule, compatible with the presence of a unique transmembrane spanning domain.
  • This protein sequence contained 6 cysteine residues in the extracellular part of the molecule, 4 (positions 78, 104, 181 and 229) of which may be involved in internal disulfide bonds. The others (cysteine 440 and 443) are too close, but might be involved in receptor dimerization. In addition, 3 putative sites for N-glycosylation are present. A schematic representation of this receptor was shown in Figure 27.
  • nucleotide sequence of XNPR-C presented 84%, 83%, 85%, 84%, 83%, 87% and 86% identity with partial sequences of NPR-C from Bufo marinus (453 nt), human (793nt), bovine (674 nt), mouse (629 nt), rat (706nt), and eel (166). This represented 37, 35, 32 and 38%) of the entire coding sequence of the natriuretic peptide receptor-C of human, bovine, mouse and rat respectively, but only 9.5% of the eel NPR-C sequence. However, results were much more impressive for the deduced protein sequence.
  • XNPR-C had 73, 73, 72, 71, 57% identity to NPR-C of the following species, human, bovine, rat, mouse and eel, respectively. This percentage reached 85% of homology with the human sequence. The highest score, 86% of identity (94%) homology), was naturally obtained with the published partial sequence (151 aa) of the frog Bufo marinus. Interestingly, two other Xenopus sequences, XGC-1 and XGC-2, showing homology with the protein were found in the database (Figure 26). Their percentages of identity were 27 and 34%, respectively. However these identity scores were similar to those obtained when the sequence was matched against mammalian NPR-A and NPRB ( ⁇ 30-31 %).
  • defolliculated oocytes were injected with 30 ng of XNPR-C capped mRNA.
  • oocytes were incubated with increasing concentrations of
  • I-ANP in the presence or absence of 10 ⁇ M of rat ANP ⁇ -28.
  • Receptor saturation curves were obtained by incubating oocytes (8/sample) increasing concentration of 125 I-ANP with (Non specific) or without (Total) 10 ⁇ M ANP for 150 min at 4°C. Specific binding was determined by subtraction the non-specific from the total binding. Curve fitting and graphs were performed using Graphprism software (ISI). A non-linear regression analysis of the resulting saturation curve was used to determine the ligands/receptor interaction parameter KD and Bmax. Experiments wereperformed twice in triplicates. The saturation curve showed specific saturation of expressed binding sites for peptide concentrations over 150 pM ( Figure 28).
  • Non linear regression of the specific binding curve (obtained after subtraction of nonspecific binding) showed a maximum binding value (Bmax) of 57 ⁇ 2.3 X 10 sites/oocytes and KD of 96+ 4.23 pM. In contrast, uninjected oocytes showed no specific binding.
  • Table HI depicts the displacement of 1251- ANP binding by natriuretic peptides and VTP- related neuropeptide analogs. IC50 values for the different analogs tested have been calculated from displacement curves of the 1251- ANP binding in NPR-C overexpressing oocytes. Data were extracted using Graphprism software.
  • Defolliculated oocytes were injected as described above for binding assays and incubated for 4 days prior stimulation. Oocytes (10/sample) were preincubated within a solution of
  • PAC1 and XNPR-C receptor mRNAs were co-injected into oocytes to study the interaction of these 2 receptors on AC activity.
  • Oocytes (10/sample) were preincubated for 15 min at room temperature, within a solution of 1 mM IBMX also containing 2 ⁇ M FSK (A and B), or 50 nM PACAP (C) or 50 nM ANP (D). The specified peptides were then incubated for another 15 min period, before cAMP extraction. Cyclic AMP concentrations were measured by RIA. Experiments were conducted in triplicates. As previously described, oocytes were pre-stimulated with 2 ⁇ M FSK.
  • oocytes were coinjected with XNPR-C and PAC1 mRNAs.
  • coinjected oocytes were incubated with or without 50 nM PACAP-38 for 30 min.
  • Levels of cAMP were 40% higher when cells were treated with PACAP-38 than when treated with FSK alone ( Figure 32C).
  • the XNPR-C receptor was also compared to all Xenopus sequences available in the database. Two Xenopus sequences had significant homology ( Figure 26). These encode two guanylate-cyclase containing proteins, named XGC-1 and XGC-2 (Genbank access number, AB025111.1 and AB025111.2, respectively). Like XNPR-C, XGC sequences had an extracellular domain, a putative transmembrane domain, but included a very long intracellular tail that contained the guanylate cyclase activity. Moreover, widely spread homologies with the XNPR-C sequence were observed in the extracellular region. Among the numerous similarities, the perfect alignment and conservation of all the 6 cysteine residues was noteworthy. Moreover, the NP receptor signature domain (GPXCXYXXAXVXRXXXHW) was conserved within these 3 Xenopus sequences.
  • Type-C natriuretic peptide receptors have been long considered to be clearance receptors for circulating natriuretic peptides.
  • the clearance function appears to require dimerization of NPR-C monomers and intemalization of the ligand/receptor complex. Modification of the human receptor sequences affecting the residues Cysteine or the tyrosine triggered a 50% inhibition of the receptor intemalization (Cohen D, et al. (1996). J Biol Chem, 271 : 9863-9869).
  • the present Xenopus NPR-C receptor showed a perfect identity of sequence in these crucial positions. More recently, targeted NPR-C gene disruption (Matsukawa N, et al.
  • NPR-C might also be coupled to a signal transduction pathway.
  • Studies performed by Anand- Srivastava (Anand-Srivastava MB and Trachte GT (1994) Pharmacol Rev, 45: 455-497, Anand-Srivastava MB, et al. (1996) J Biol Chem, 271: 19324-19329) and others (Murthy KS, and Makhlouf GM (1999) J Biol Chem. 274:17587-17592) proposed that NPR-C activation results in an inhibition of adenylyl cyclase activity and/or increased intracellular calcium through a pertussis toxin-sensitive Gi.
  • NPR-C regulator might regulate PACAPPACl activity in Xenopus. Injection of NPR-C and PACl mRNAs alone and in combination were used to test this hypothesis.
  • the ability of natriuretic peptides and neuropeptides to modulate the FSK-induced elevation of cAMP was tested. Natriuretic peptides, as expected, reduced the cAMP contents, through NPR-C receptors but did not interact with PACl receptors.
  • PACAP-38 significantly enhanced the FSK action on cAMP production. Between these extreme cases, PACAP-27, which interacted with each of the receptors, displayed an intermediate behavior.
  • PACAP-38 or ANP Antagonistic effects on cAMP production were studied by treatment with natriuretic peptides and neuropeptides.
  • PACAP-38-induced stimulation of cAMP contents was abolished and reverted by either natriuretic peptides or VTP analogs through their interaction with NPR-C receptors coupled negatively with AC.
  • ANP-induced-inhibition of cAMP basal levels was counterbalanced by PACAP stimulations.
  • PACAP-38 and PACAP-27 stimulatory effects were strongly reduced by co-stimulation of NPR-C receptors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des procédés et des compositions de régulation de la prolifération et/ou de la survie des neurones en vue de traiter l'apoptose et/ou les lésions neuronales, ou le cancer et diagnostiquer les tumeurs neuronales au moyen de composés tels que des peptides natriurétiques ou des neuropeptides relatifs à PHI afin qu'il y ait interaction avec des sous-types de récepteurs peptidiques sur les neurones. Cette invention porte également sur un nouveau récepteur des neurones qui inhibe la prolifération en réponse aux neuropeptides natriurétiques et relatifs à PHI, et sur un nouveau récepteur natriurétique de type C.
PCT/US2000/024457 1999-09-01 2000-09-01 Nouveaux recepteurs peptidiques natriuretiques, composes d'interaction et procedes de regulation de la proliferation et/ou de la survie des neurones WO2001016295A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73522/00A AU7352200A (en) 1999-09-01 2000-09-01 Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15185299P 1999-09-01 1999-09-01
US60/151,852 1999-09-01

Publications (2)

Publication Number Publication Date
WO2001016295A1 true WO2001016295A1 (fr) 2001-03-08
WO2001016295A9 WO2001016295A9 (fr) 2002-09-26

Family

ID=22540500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024457 WO2001016295A1 (fr) 1999-09-01 2000-09-01 Nouveaux recepteurs peptidiques natriuretiques, composes d'interaction et procedes de regulation de la proliferation et/ou de la survie des neurones

Country Status (2)

Country Link
AU (1) AU7352200A (fr)
WO (1) WO2001016295A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103702A1 (fr) * 2002-06-10 2003-12-18 Mondobiotech Laboratories Anstalt Utilisation de composes presentant l'activite biologique du peptide intestinal vasoactif pour traiter une sarcoidose
WO2007115175A2 (fr) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Constructions de peptides natriurétiques cycliques
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022610A1 (fr) * 1996-11-15 1998-05-28 I.D.M. Immuno-Designed Molecules Nouveaux complexes polymeriques pour la transfection d'acides nucleiques, avec des residus destabilisant des membranes cellulaires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022610A1 (fr) * 1996-11-15 1998-05-28 I.D.M. Immuno-Designed Molecules Nouveaux complexes polymeriques pour la transfection d'acides nucleiques, avec des residus destabilisant des membranes cellulaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DREWETT J.G. ET AL.: "Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 255, no. 2, 1990, pages 497 - 503, XP002933896 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103702A1 (fr) * 2002-06-10 2003-12-18 Mondobiotech Laboratories Anstalt Utilisation de composes presentant l'activite biologique du peptide intestinal vasoactif pour traiter une sarcoidose
JP2005535607A (ja) * 2002-06-10 2005-11-24 モンドバイオテック・ラボラトリーズ・アンスタルト サルコイドーシスを治療するための血管作動性腸管ペプチドの生物活性をもつ化合物の使用
CN1313149C (zh) * 2002-06-10 2007-05-02 蒙杜生物科技安斯塔特实验室 具有血管活性肠肽的生物学活性的化合物在治疗结节病中的用途
US7951778B2 (en) 2002-06-10 2011-05-31 Mondobiotech Ag Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
WO2007115175A2 (fr) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Constructions de peptides natriurétiques cycliques
US7622440B2 (en) 2006-03-30 2009-11-24 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580747B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs

Also Published As

Publication number Publication date
WO2001016295A9 (fr) 2002-09-26
AU7352200A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
von Gall et al. Mammalian melatonin receptors: molecular biology and signal transduction
Balasubramaniam Clinical potentials of neuropeptide Y family of hormones
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
US20070197445A1 (en) Compounds for control of appetite
CA2597065A1 (fr) Compositions et methodes se rapportant aux recepteurs couples a la proteine g soluble (sgpcr)
US20150057430A1 (en) Compound, use and method
US20020082409A1 (en) Stresscopins and their uses
JP2018537529A (ja) プロテアーゼ活性化受容体２のモジュレーター
CZ20032395A3 (cs) Metoda identifikace sloučenin regulujících svalovou hmotu
US20060149050A1 (en) Isolation and method of using tissue growth-inducing Frzb
Sousa et al. NPY signalling pathway in bone homeostasis: Y1 receptor as a potential drug target
US20010016319A1 (en) Cloning of a novel G-protein coupled 7TM Receptor
WO2001016295A1 (fr) Nouveaux recepteurs peptidiques natriuretiques, composes d'interaction et procedes de regulation de la proliferation et/ou de la survie des neurones
JPH11502104A (ja) ゴナドトロピン放出ホルモン受容体活性の抑制および調節
JP6587677B2 (ja) 魚の生殖におけるニューロキニンｂのアンタゴニスト
US7217808B2 (en) RFRP-3 and DNA thereof
Massotti et al. Regulation of diazepam binding inhibitor in rat adrenal gland by adrenocorticotropin
JP2008013436A (ja) 血管形成促進剤
US6274333B1 (en) Type-2 neurotensin receptor (NT-R2)
CA2180957C (fr) Clonage et production par recombinaison d'un ou plusieurs recepteurs du facteur liberateur de la corticotrophine
Yang et al. Involvement of somatostatin receptor subtypes in membrane ion channel modification by somatostatin in pituitary somatotropes
US6277960B1 (en) cDNA clone HNFDY20 that encodes a novel human 7-transmembrane receptor
US6482608B1 (en) Cloning and recombinant production of CRF receptor(S)
US7345018B2 (en) Method of treating side effects induced by therapeutic agents
US20040014055A1 (en) Gene coding for erbin, and diagnostic and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/32-32/32, DRAWINGS, REPLACED BY NEW PAGES 1/31-31/31; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP